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 Staphylococcus aureus is a ubiquitous organism causing world-wide morbidity 
and mortality.  This species readily develops resistance to antimicrobial agents.  Current 
dosing strategies are based, in part, on minimum inhibitory concentrations (MICs).  
This susceptibility test fails to detect the presence of first-step resistant mutants often 
present in large heterogeneous populations of infecting bacteria.  Dosing strategies 
based on MIC results may, in fact, allow for the selective proliferation of resistant 
subpopulations.  The mutant-prevention concentration (MPC) is the drug concentration 
at which all first-step resistant mutants will be eradicated along with the susceptible 
cells.  Determination of the mutant-selection window (MSW) is possible using MIC and 
MPC data.  When considered together with achievable drug concentrations in human 
bodily sites, the MSW helps determine which antimicrobials are likely to select for 
resistance.   
MIC and MPC testing on clinical isolates of methicillin-susceptible (MSSA) and 
-resistant (MRSA) S. aureus was performed.  Characterization via the polymerase chain 
reaction, sequencing, and electron microscopy (EM) was done on selected organisms 
recovered from MPC studies (MPC-recovered).  MIC and MPC testing was performed 
on organisms isolated sequentially from patients with recurring S. aureus infections.  
Pulsed field gel electrophoresis was performed on these sequential isolates.  
Based on the MIC and the MPC values, the most potent agents for systemic 
MSSA and MRSA infections are gemifloxacin and vancomycin, respectively.  Re-
testing MPC-recovered populations by the MIC showed increased MIC results 
compared to the parent populations.  Macrolide-resistance genes were discovered in S. 
aureus MPC-recovered populations; in contrast, parental isolates lacked these resistance 
determinants.  EM revealed an increase in cell wall thickness of a vancomycin MPC-
recovered population compared to its parental population.  Moxifloxacin and 
vancomycin had the lowest and narrowest MSWs for systemic MSSA and MRSA 
 ii
infections, respectively, compared to the other agents tested.  Sequential isolates 
showed no change in MIC and MPC values. 
The data presented provides evidence for the application of the MPC test to S. 
aureus organisms.  The MPC data is significant when determining appropriate dosing 
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1.1 Staphylococcus aureus 
  1.1.1 Characteristics 
Staphylococcus aureus organisms possess a number of characteristics, including 
traits common to all staphylococci as well as traits unique to S. aureus.  The 
characteristics unique to S. aureus can be used to differentiate this species from other 
Staphylococcus species.  A number of identifiable characteristics of staphylococci 
include a Gram-positive stain, the presence of catalase, coccoid shape, and an 
appearance in grape-like clusters.  Murray et al (1998c) describe the enzyme, coagulase, 
and protein A as unique characteristics of the species, S. aureus.  Both protein A and 
coagulase protect S. aureus from immune defenses.  S. aureus commonly exists as 
normal flora, but may cause disease under certain circumstances. 
1.1.2 Diseases 
S. aureus is a ubiquitous organism causing a variety of human diseases either by 
a toxin or by the direct invasion and destruction of tissue.  Murray et al (1998c) 
describe some diseases that may be caused by S. aureus.  These include toxin-mediated 
diseases (scalded skin syndrome, toxic shock syndrome, and rapid onset food 
poisoning), cutaneous infections (cellulitis, impetigo, folliculitis, furuncles, carbuncles, 
and post-surgical wound infections), urinary tract infections, as well as infections of the 
respiratory tract.  Also, patients may develop bacteremia, osteomyelitis, or endocarditis 
as a result of a S. aureus infection.  S. aureus is an opportunistic pathogen associated 
with nosocomial infections.  Nosocomial infections are those defined as occurring in 
patients that have been hospitalized for ≥48 hr.  S. aureus is the most virulent of the 
staphylococci and, hence, can cause human infection easily.  S. aureus is the most 
studied Staphylococcus species likely because it is commonly associated with human 





The tendency for S. aureus to develop resistance to antimicrobial agents is a 
major concern.  After the development of resistance to methicillin, clinical isolates of S. 
aureus also resistant to other antimicrobials were isolated.  For example, resistance to 
erythromycin, rifampin, streptomycin, and tetracycline have been found amongst S. 
aureus isolates (Skurray et al, 1988).  Because of the virulence of this organism in both 
community and hospital acquired infections, the development of resistance is of great 
concern. 
 1.1.3.1 Resistance to β-lactams 
Shortly after the introduction of penicillin in the early 1940’s, S. aureus began 
developing resistance to this antimicrobial agent (Rammelkamp and Maxon, 1942).  It 
was shown by Bondi and Dietz (1945) that the resistance was due to an enzyme, β-
lactamase.  β-lactamase degrades the antimicrobial agent before it reaches its target.  
The genes that code for β-lactamase are plasmid-borne and can, therefore, be easily 
passed on from bacterial cell to cell (Oliveira et al, 2002).  As a result, novel semi-
synthetic penicillins with the ability to withstand the destructive effect of β-lactamase 
were developed.   
Methicillin, nafcillin, oxacillin, and cloxacillin are among the semi-synthetic 
penicillins resistant to the destruction by β-lactamase (Rolinson and Sutherland, 1973).  
Reports of S. aureus resistant to methicillin (MRSA), however, emerged in the 1960’s 
(Kagan et al, 1964; Seligman, 1966).  MRSA possess the 2.1 kb mecA gene embedded 
into a block of ‘foreign’ DNA which makes up the ‘mec element’ or ‘staphylococcal 
chromosomal cassette’ (SCCmec) (Oliveira et al, 2002).  The mec element incorporates 
itself into the S. aureus chromosome at a specific location.  The mecA gene codes for a 
penicillin-binding protein (PBP2A), which has a low affinity for β-lactam antibiotics 
(Oliveira et al, 2002).  It is the lack of β-lactam agent binding to the cell that allows the 
resistant organisms to proliferate in the presence of the newer β-lactam antibiotics.  
MRSA is common and this organism is easily disseminated.  Recent data suggest that 
30% of inpatient isolates and 15% of outpatient isolates in the United States are 
resistant to methicillin (National Nosocomial Infections Surveillance or NNIS, 2000).  
In Canada, however, the percentage of resistant strains has remained low (<6%) 
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(Diekema et al, 2001).  These data are summarized in Table 1.1.  If resistance rates 
continue to rise in Canada as they have in the United States, the mortality and morbidity 
would be expected to increase significantly among infected Canadian patients.  
  1.1.3.2 Resistance to Vancomycin  
Despite the ability of S. aureus organisms to develop resistance to different 
agents, the majority of strains are susceptible to the glycopeptide vancomycin.  
Vancomycin resistance in S. aureus isolates can be induced experimentally, but because 
of the difficulty in inducing this resistance, it was thought that the natural tendency to 
develop resistance to this agent was unlikely for S. aureus (Moellering, 1998).  Another 
factor that increased confidence and reliance on vancomycin is that after 20 years of 
use, no resistant strains of staphylococci had been reported (Srinivasan et al, 2002). 
Because of these factors, vancomycin quickly became the antibiotic of choice for 
serious MRSA infections (Hamilton-Miller, 2002).   
In 1996, however, the first clinical case of vancomycin-intermediate S. aureus 
(VISA) was isolated from a patient in a Japanese hospital (Hiramatsu et al, 1997b).  
Since then, healthcare professionals have been concerned because vancomycin is an 
important antimicrobial for S. aureus infections.  Although rare, some individuals have 
recently had infections caused by S. aureus strains with reduced-susceptibility to 
vancomycin (Srinivasan et al, 2002).  Vancomycin-resistant S. aureus (VRSA) and 
VISA are those isolates with minimum inhibitory concentration (MIC) values of >32 
µg/ml and 8-16 µg/ml, respectively, according to the National Committee for Clinical 
Laboratory Standards (NCCLS) (NCCLS, 2001a).  Research on the mechanism of 
resistance is ongoing and necessary to help understand the emergence of S. aureus with 
reduced susceptibility to vancomycin. 
 Very few clinical S. aureus isolates have been reported as harboring the 
vancomycin-resistance genes common to Enterococcus species, however, two articles 
in 2002 reported the existence of a vanA genotype in clinical S. aureus isolates (CDC, 
2002a,b).  In the studies of Mu3 and Mu50, two clinical VRSA strains, the resistance 
was not due to the transfer of either the vanA or vanB vancomycin-resistance genes 
(Hiramatsu, 1998).  The development of vancomycin-resistant populations may occur as 
a result of selection for these particular phenotypes from a subpopulation of a 
 3




 Resistance Rates (%) 
 U.S.A.a Canadab 
Inpatient 30  <6  
Inpatient Intensive 
Care Unit (ICU) 
50  <6  
Out Patient 15  <6  
 
aNational Nosocomial Infections Surveillance (NNIS), 2000 
bDiekema et al, 2001 
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heterogeneous population of cells (Ike et al, 2001).  A heterogeneous population of cells 
is a population consisting of a majority of susceptible cells and far fewer resistant cells 
that are created by mutation(s) or acquisition of resistance genes (Srinivasan et al, 
2002).  One difference noted between a VISA and vancomycin-susceptible S. aureus 
(VSSA) is the thickening of the cell wall in VISA isolates (Smith et al., 1999b).  One 
theory of resistance based on the thickening of the cell wall comes from Hiramatsu et al 
(2002).  The authors state, “…the thickening causes the increased intra-cell-wall 
trapping of vancomycin molecules and prevents their reaching targets on the 
cytoplasmic membrane” (Hiramatsu et al, 2002).  The studies of VRSA are preliminary 
and though little is known about the mechanism of resistance, it is suggested that 
thickening of the cell wall may be a phenotypic resistance determinant for S. aureus 
isolates with decreased susceptibility to vancomycin (Cui et al, 2003). 
Hiramatsu et al (2002) state that vancomycin resistance is acquired by a multi-
step genetic phenomenon.  The authors found that VRSA organisms are extremely 
unstable and lose their resistant phenotype when there is a lack of vancomycin selective 
pressure.  The resistant strain is then replaced by a faster-growing revertant.  They 
conclude that “…hetero-VRSA is the essence of vancomycin resistance from which 
vancomycin selects VRSA and to which it returns when selective pressure is lifted” 
(Hiramatsu et al, 2002).  If vancomycin resistance were to develop worldwide and 
spread easily, this would be devastating because of the current reliance on vancomycin 
for therapy in infected patients.  
 Healthcare professionals are now focusing on alternative therapies for MRSA 
infections.  Other antimicrobials showing clinical success with MRSA infections 
include linezolid, quinupristin/dalfopristin, and teicoplanin.  Because of the possibility 
of resistance to both old and new antimicrobials, reliance on one agent should be 
avoided. 
   1.1.3.3 Resistance to Macrolides 
Recently, the macrolides have become more commonly used for treatment of S. 
aureus infections.  These agents are being used extensively in not only human clinical 
practice, but also in the poultry and livestock industries (Devriese, 1980; Owens et al, 
1988; Brown and Scassera, 1990; Skeeles, 1991; Westh et al, 1991; Nawaz et al, 2000).  
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The widespread plus prolonged use of these agents has led to an increase in resistance 
to the macrolides (Weisblum and Demohn, 1969; Andremont et al, 1986; Arthur et al, 
1987; Nawaz et al, 2000).  Resistance to macrolides is accomplished by either target 
modification or an efflux system.  Target modification is carried out by the 
erythromycin resistance methylase (erm) genes and efflux is a result of the macrolide 
efflux genes (mefA/E gene or the msrA/B gene).  If resistance to macrolides continues to 
increase, it will compromise the use of this family of antimicrobial agents.   
1.1.3.4 Resistance to Quinolones 
The quinolone agents are potent antimicrobials that have proven successful for 
treating many infections.  Unfortunately, many hospital-acquired S. aureus isolates 
demonstrate resistance to quinolones (Blumberg et al, 1991; Neu, 1992; Acar and 
Goldstein, 1997; Zhao et al, 2003).  Many community-acquired isolates, however, are 
still susceptible to quinolones (Schito et al, 1996; Gorak et al, 1999; Lister, 2000; Ma et 
al, 2002; Zhao et al, 2003).  In a study done by Almer et al in 2002, 49% of 
community-acquired S. aureus were susceptible to quinolone agents.  In Saskatoon, 
over 95% of S. aureus isolates remain susceptible to ciprofloxacin (Blondeau-personal 
communication).  This creates optimism in the ability of quinolones to successfully treat 
infections caused by S. aureus.  As novel quinolones are being developed, the 
possibility of resistance should be considered and avoided through proper use of these 
agents as to maintain their effectiveness. 
 1.2 Streptococcus pneumoniae   
 Although the focus of this project was essentially with the organism S. aureus, 
some data were assessed for Streptococcus pneumoniae isolates.  S. pneumoniae is a 
Gram-positive organism causing bacteremia, meningitis, otitis media, pneumonia, and 
sinusitis (Murray et al, 1998c).  Resistance of this organism to antimicrobial agents is 
increasing worldwide.  Macrolides are being used in patients with respiratory tract 
infections caused by pneumococci.  Pihlajamaki et al (2001) have studied the 
correlation between macrolide use and resistance in different geographical regions.  
They found that the prevalence of macrolide-resistant S. pneumoniae was higher in 
regions with greater macrolide use.  S. pneumoniae may become resistant to macrolides 
by target modification or efflux (Gay and Stephens, 2001).  Efflux is accomplished by 
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the mefA/E gene and results in low to moderate levels of resistance (Montanari et al, 
2003).  Target modification is accomplished either by the erm class methylases which 
results in high level resistance or by mutations in the 23S rRNA (Montanari et al, 
2003).  Strains with inducible resistance have ermB or ermB plus mefE (Nishijima et al, 
1999).  Strains with non-inducible resistance have only mefE (Nishijima et al, 1999).  
MefA and mefE are very similar and are often not distinguished by conventional 
Polymerase Chain Reaction (PCR) methods, therefore, these genes are regarded as a 
single class often referred to as mefA (Sutcliffe et al, 1996; Perez-Trallero et al, 2001).  
S. pneumoniae strains with intermediate-resistance or resistance to penicillin are more 
likely to be concomitantly resistant to other classes of antimicrobial agents, including 
macrolides, than S. pneumoniae strains sensitive to penicillin (Noreddin et al, 2002).  S. 
pneumoniae is a clinically important pathogen and the recent increase in resistance 
observed in this organism is disconcerting. 
1.3 Antimicrobial Agents 
1.3.1 Macrolides 
1.3.1.1 General Overview 
Macrolide agents include erythromycin, josamycin, midecamycin, 
oleandomycin, rosaramycin, roxithromycin, and spiramycin (Periti et al, 1989).  
Erythromycin, the first macrolide antibiotic, was isolated from Streptomyces erythreus 
and was marketed in 1952 (Blondeau et al, 2002a).  Macrolides are basic and are mostly 
absorbed in the alkaline intestinal environment (Periti et al, 1989).  The basic structure 
of macrolides is the macrolide ring bound to two sugars (desosamine and cladinose) 
(Zuckerman, 2000).  Azithromycin and clarithromycin are new azalide agents that were 
semi-synthetically modified from original macrolides (Periti et al, 1989).  Azithromycin 
contains a nitrogen atom in the macrolide ring resulting in a 15-membered structure, 
whereas, clarithromycin is a 14-membered compound which lacks the nitrogen atom in 
its structure. (Danesi et al, 2003).  Approval of azithromycin by the Food and Drug 
Administration (FDA) occurred in 1992.  This agent was developed to better withstand 
acid conditions compared to the previously developed macrolides, such as erythromycin 
(Zuckerman, 2000).  Azithromycin and clarithromycin, the “new” macrolides, have a 
much lower incidence of side effects as well as a broader spectrum of activity compared 
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to older macrolides (Blondeau et al, 2002a).  This family of antibiotics enters pleural 
and ascitic fluids, middle ear exudates, and the sputum, however, these drugs do not 
normally enter the cerebral spinal fluid in clinically useful concentrations (Periti et al, 
1989).  The macrolides are often used as an alternative to penicillin (Pihlajamaki et al, 
2001).  These agents are becoming more common in treating upper respiratory 
infections as well as some S. aureus infections.  The broad spectrum of these agents 
allows them to be useful in the treatment of a variety of bacterial infections (Berry et al, 
1998; Donati et al, 1999; Danesi et al, 2003).   
  1.3.1.2 Mechanism of Action   
Macrolide antibiotics work by blocking protein synthesis.  These agents 
reversibly bind to the 50S ribosomal subunit (Periti et al, 1989).  This, in turn, blocks 
transpeptidation or translocation, hence preventing protein chain elongation.  This 
family of antimicrobials is bacteriostatic which means that they do not kill the cells, but 
prevent them from growing. 
1.3.1.3 Mechanism of Resistance 
Resistance toward macrolides may evolve in different ways.  Methylation of the 
23S ribosomal RNA is one way in which an organism may become resistant to a 
macrolide (Lim et al, 2002).  This change prevents the antibiotic from binding to the 
target site.  The antibiotic cannot act on the organism without binding to its target site, 
therefore, the organism is rendered resistant.  This resistance is achieved via one or 
more of the erm genes (Wondrack et al, 1996; Pechere, 2001; Lim et al, 2002).  There 
are seventeen different types of erm genes known (Nawaz et al, 2000), however, ermA, 
ermB, and ermC are most common in staphylococci.  Another mechanism of resistance 
that has been observed is efflux (Lim et al, 2002).  This is the pumping out of the 
antibiotic from the cell, preventing it from reaching its target.  This mechanism of 
resistance is accomplished by the macrolide efflux gene (mefA/E) in S. pneumoniae 
(Lim et al, 2002) or by the macrolide-specific resistance gene (msrA/msrB) in S. aureus 
(Matsuoka et al, 2003).  Resistance to macrolides may also occur via enzymatic 
degradation (Pechere, 2001).  Many different enzymes conferring macrolide resistance 
have been discovered in Enterobacteriaceae and staphylococci (Wondrack et al, 1996; 
Pechere, 2001).  This resistance may have evolved naturally to ensure survival of 
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bacteria in environments harboring the antimicrobial products of Streptomyces species 
(Pechere, 2001). 
1.3.1.4  Side Effects 
The newer macrolides such as azithromycin and clarithromycin were developed 
to decrease the severity of the side effects that accompanied the older macrolides.  
Some severe side effects more common in the older macrolides include cholestatic 
hepatitis (Hautekeele, 1995) and cranial nerve toxicity (Snavely, 1984).  Some less 
serious, but more frequent side effects in the earlier developed macrolides include 
nausea, cramping, and diarrhea (Blondeau et al, 2002a).  The newer macrolides 
(developed in the 1980’s and marketed in the 1990’s to present day) are clinically 
efficacious as well as having fewer, minor side effects.  
1.3.2 Clindamycin 
1.3.2.1 General Overview 
Clindamycin belongs to the family of lincosamides and was isolated from the 
species Streptomyces lincolnensis (Murray et al, 1998b).  Its use has been appreciated 
for treating malaria (Pukrittayakamee et al, 2004), toxoplasmosis (Fung and 
Kirschenbaum, 1996), and babesiosis (Krause, 2003).  As well, clindamycin is active 
against staphylococci and streptococci (Leclercq, 2002).  Delivery of this agent is 
accomplished orally, intravenously, or intramuscularly (Gilbert et al, 2002). 
1.3.2.2 Mechanism of Action 
Clindamycin acts on bacteria in a similar manner as the macrolides.  
Clindamycin binds to the 50S ribosomal subunit, blocking protein elongation.  This 
agent interferes with the binding of the tRNA complex, thereby inhibiting peptidyl 
transferase, an enzyme responsible for transferring linked amino acids to the aminoacyl 
site from the peptidyl site in the tRNA (Murray et al, 1998b).  This agent does not result 
in the death of the organism, but inhibits the organism from further growth.   
1.3.2.3 Mechanism of Resistance 
Leclercq (2002) reviews the three mechanisms of resistance to lincosamides. 
Methylation of the 23S rRNA alters the drug target site.  This resistance is plasmid-
mediated and confers broad-spectrum resistance to both macrolides and lincosamides.  
Efflux and drug inactivation are the other two mechanisms of resistance that have been 
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observed in organisms resistant to lincosamides.  These three resistance mechanisms 
have been found naturally in macrolide and lincosamide producers to protect 
themselves against the antimicrobial products they produce. 
1.3.2.4 Side Effects 
Serious side effects that have been connected to the use of clindamycin include 
hepatitis and pseudomembranous colitis (Gilbert et al, 2002).  More commonly 
observed, however, are the less serious adverse effects of fever and rash. 
1.3.3 Cephalosporins 
1.3.3.1 General Overview 
The antibiotics cefazolin, cephalexin, cefuroxime, and cefotaxime belong to the 
family of cephalosporins.  Cephalosporin agents, originally recovered from the mold 
Cephalosporium acremonium, are β-lactam antibiotics comprised of a β-lactam ring 
fused with a dihydrothiazine ring (Nightingale et al, 1975).   Cefazolin is a first-
generation, semi-synthetic cephalosporin and is administered parenterally 
(intramuscularly or intravenously) (Nightingale et al, 1975; Gilbert et al, 2002).  
Cephalexin, like cefazolin, is a first generation cephalosporin, but unlike cefazolin, 
cephalexin is administered orally (Gilbert et al, 2002).  Cefuroxime and Cefotaxime are 
second and third-generation cephalosporins, respectively.  Cefuroxime is administered 
either orally or intravenously, whereas cefotaxime is administered parenterally.  
Cefazolin levels remain high in the blood for approximately 90 min (Nishida et al, 
1969; Shibata and Fujii, 1970; Lopez-Sosa et al, 1993).  Also, cefazolin is almost 
completely recovered in the urine after intramuscular or intravenous administration 
(Nishida et al, 1969; Shibata and Fujii, 1970).  Cephalosporins initially possessed a 
broad spectrum of activity against most Gram-positive and Gram-negative bacteria 
(Nightingale et al, 1975).  Unfortunately, some Gram-negative organisms have 
developed resistance to these agents and this has compromised their use in infected 
patients (Murray et al, 1998b).   
1.3.3.2 Mechanism of Action 
Cephalosporins act on their target cells by interfering with the penicillin-binding 
proteins (PBPs).  This interference results in the destabilization of the cell wall, leading 
to cell death. 
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1.3.3.3 Mechanism of Resistance 
Resistance to cephalosporins may occur via β-lactamase (described in section 
1.1.3.1) (Livermore, 1987).  Mutations in fusA, the gene that codes for an elongation 
factor, may also result in resistance to cephalosporins (O’Neill et al, 2002).  The mecA 
gene may also confer resistance to cephalosporins by altering the penicillin binding site, 
preventing cephalosporins from binding to the target protein (Mandell, 1998).   
1.3.3.4 Side Effects 
Gilbert et al (2002) list side effects that occur with cephalosporin treatment.   
Significant hematological and hepatic effects have been correlated with cephalosporin 
treatment.  Frequent side effects include rash, fever, and diarrhea. 
1.3.4 Penicillins 
1.3.4.1 General Overview 
Like the cephalosporin agents, penicillin agents are also β-lactams.  Murray et al 
(1998b) describe penicillin in detail.  The basic structure is an organic acid with a β-
lactam ring fused to a 5-membered thiazolidine ring.  Penicillin was first obtained from 
a mold called Penicillium chrysogenum and from this mold natural penicillin agents like 
benzylpenicillin (penicillin G) and phenoxymethyl penicillin (penicillin V) were 
developed.  Penicillin was one of the first antibiotics on the market and proved to be 
very effective with low toxicity.  Shortly after its introduction, however, resistance 
emerged to this drug.  New β-lactam agents were created to bypass the resistance 
displayed by S. aureus.  For example, cloxacillin, dicloxacillin, methicillin, nafcillin, 
and oxacillin are β-lactamase-resistant.  Cloxacillin is absorbed from the gastro-
intestinal tract and a small amount of the drug is lost due to acid hydrolyzation (Soldin 
et al, 1980).  This is a major disadvantage for cloxacillin, however, once absorbed, it is 
very effective against β-lactamase-producing S. aureus strains (Nauta and Mattie, 1975; 
Soldin et al, 1980).   
Although their spectrum of activity is limited, the aminopenicillins (ampicillin 
and amoxicillin) were the first penicillin agents active against Gram-negative bacilli 
(Murray et al, 1998b).  Later, the carboxypenicillins (carbenicillin and ticarcillin) and 
the ureidopenicillins (mezlocillin and piperacillin) were created and have a broad 
spectrum of activity against Gram-negative bacteria.  Piperacillin/tazobactam was 
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subsequently developed as a combination of piperacillin and the β-lactamase inhibitor, 
tazobactam.  Because tazobactam is structurally similar to β-lactam drugs, it binds to β-
lactamase enzymes, preventing them from destroying the piperacillin.  Penicillins can 
be administered orally, intramuscularly, or intravenously.  
1.3.4.2 Mechanism of Action 
Penicillins act by binding to the PBP situated within the peptidoglycan of the 
cell, thus causing destabilization of the cell wall (preventing cell wall synthesis) 
(Tomasz, 1979).  The PBPs are the enzymes responsible for the catalysis of reactions 
necessary for cell wall synthesis and include D-alanyl-D-alanine-carboxy-peptidases 
and transpeptidases (Murray et al, 1998a).  Penicillin causes the cell to release autolytic 
enzymes that degrade the cell wall (Tomasz, 1979).  Degradation of the cell wall results 
in the cell bursting.  In addition to cell wall destruction, some of the more recently 
developed penicillin agents have the ability to inhibit or resist bacterial β-lactamases.  
1.3.4.3 Mechanism of Resistance 
Organisms may become resistant to penicillin in a number of ways.  Resistance 
may be accomplished through the failure of the antimicrobial agent to cross the 
membrane and, hence, reach the drug’s target.  This is primarily associated with Gram-
negative organisms.  Two other mechanisms of resistance that are common to both 
Gram-positive and Gram-negative bacteria are the alteration of the PBPs and the 
production of β-lactamase.  Many S. aureus isolates have now developed resistance to 
the newer penicillin agents by acquiring the mec element.  This gene was discussed in 
section 1.1.3.1. 
1.3.4.4 Side Effects 
Like most other antibiotics, with the administration of penicillin, there is a risk 
of side effects.  Possible severe side effects include hypersensitivity, seizures, platelet 
dysfunction, neutropenia, hemolytic anemia, liver problems, encephalopathy, and 
interstitial nephritis (RxList.com, 2003a).  When one is allergic to penicillin, an 
alternative form of antimicrobial therapy is necessary.  Some commonly experienced 
and less serious side effects include rash, diarrhea, chills, fever, edema, and electrolyte 




1.3.5.1 General Overview 
In 1962, the first quinolone, nalidixic acid, was introduced (Lesher et al, 1962).  
The development of fluoroquinolones involved the addition of fluorine at the six-
position of a quinolone agent (Goldstein et al, 2002).  The classical fluoroquinolones 
included ciprofloxacin, norfloxacin, and ofloxacin (Naber et al, 2001).  New 
fluoroquinolones have been developed because the classical fluoroquinolones have a 
limited spectrum of activity (Lubasch et al, 2000).  New fluoroquinolones include 
gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.  Garenoxacin (still 
undergoing investigation and not yet licensed anywhere in the world) is a new des-
F(6)quinolone that does not possess the characteristic fluorine at the six-position 
(Goldstein et al, 2002).  Garenoxacin has been shown to be very potent (Goldstein et al, 
2002), which is contradictory to the belief that the potency of recently developed 
fluoroquinolones is a result of the C-6 fluorine (Ryan et al, 2002).  Gatifloxacin and 
moxifloxacin have a methoxy group at the C-8 position and this addition results in 
increased activity against Gram-positive bacteria (Fung-Tome et al, 2001).  New 
derivatives with C-8 chlorine and C-8 methoxy moieties exhibit increased activity 
against quinolone-resistant mutants (Zhao et al, 1997; Lu et al, 2001).  The derivatives 
of the fluoroquinolones have an extended spectrum of activity and improved 
pharmacokinetic properties compared to the classical fluoroquinolones (Lubasch et al, 
2000).  Quinolones are useful for treating a wide variety of bacterial infections, 
including skin and skin structure infections caused by S. aureus, and are often 
considered as an alternative to penicillin (Lubasch et al, 2000; Blondeau et al, 2001).  
The use of quinolones for S. aureus infections has increased due to widespread 
resistance to penicillin and increasing resistance to the macrolides (Li and Nikaido, 
2004). 
1.3.5.2  Mechanism of Action 
Quinolone agents exert their bactericidal effects by inhibiting topoisomerase IV 
or DNA gyrase (topoisomerase II), enzymes critical for DNA replication (Harley et al, 
1993).  The fluoroquinolones prohibit the supercoiling of DNA, thus inhibiting DNA 
synthesis.  Two alpha (GyrA encoded by the gyrA gene) and two beta (GyrB encoded 
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by the gyrB gene) subunits make up DNA gyrase and the quinolones bind to the alpha 
subunits (Murray et al, 1998b). Topoisomerase consists of a tetramer and is encoded by 
parC and parE genes (termed glrA and grlB, respectively, in S. aureus) (Ferrero et al, 
1994).  DNA supercoiling is imperative for the survival of a cell.  Quinolones inhibit 
supercoiling, therefore, the cells cannot survive in the presence of these agents. 
1.3.5.3  Mechanism of Resistance 
Quinolone resistance has been established worldwide and fluoroquinolone 
resistance is appearing rapidly despite the fact that fluoroquinolones are novel 
antibiotics (Chen et al, 1993; Li and Nikaido, 2004).  The principal mechanism for 
resistance to fluoroquinolones is alteration of the antimicrobial target as a result of a 
mutation in the quinolone resistance-determining regions (QRDR) (Yoshida et al, 
1990).  These mutations are specifically within the genes encoding DNA gyrase (gyrA 
and gyrB) and topoisomerase IV (parC and parE) (Johnson et al, 2003).  Resistance to 
quinolones occurs in a step-wise fashion, increasing the level of resistance when in the 
presence of differing concentrations of the quinolone agent (Allen, 2003).  Efflux has 
also been observed in organisms that are resistant to quinolones (Poole, 2000).  Newer 
fluoroquinolone agents appear to be more effective against multi-drug resistant bacteria 
compared to older quinolones. 
1.3.5.4 Side Effects 
Significant side effects associated with fluoroquinolones are uncommon.  
Gilbert et al (2002) state a number of possible side effects with fluoroquinolones.  
Depending on the agent, one potential side effect is photophobia.  Also, there is a 
potential for these agents to have adverse effects on joint cartilage.  This potential side 
effect is based on observations in animal studies and, to date, no human clinical cases 
have demonstrated this effect.  However, these agents are not recommended for children 
<16 yrs of age because of the potential developmental problems in joint cartilage that 
may be associated with these agents.  For the same reason, quinolones are not 
recommended for use in pregnant women as these drugs have been shown to cross the 
placenta and may, therefore, have detrimental effects on the development of the fetus 
(Giamarellou et al, 1989).  Other side effects frequently associated with these drugs 
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include gastro-intestinal upset, central nervous system toxicity, and allergic reactions.  
These side effects are minimal for the new fluoroquinolones. 
1.3.6 Glycopeptides 
1.3.6.1 General Overview 
Glycopeptides are complex heterocyclic molecules that consist of a heptapeptide 
backbone with various attached sugars (Pfeiffer, 1981).  These agents were used in 
patients that had allergies to penicillin before alternative agents were available.  
Glycopeptides are delivered principally by the intravenous route.  One of the most 
successful glycopeptides is vancomycin.  It was obtained originally from Streptomyces 
orientalis (McCormick et al, 1955-1956).  Vancomycin is the antibiotic of choice for 
life-threatening MRSA infections (Hamilton-Miller, 2002).  Neither vancomycin, nor 
any other glycopeptide, is used for Gram-negative bacteria because the large size of the 
compounds makes it impossible for them to penetrate the outer membrane and reach 
their target in the peptidoglycan layer (Geisel et al, 2001).   
1.3.6.2 Mechanism of Action 
Glycopeptides prevent the addition of new building blocks to the growing cell 
wall.  These agents interact with the D-alanyl-D-alanine ends of the pentapeptide 
chains, which interfere with the formation of the bridges between the peptidoglycan 
chains (Murray et al, 1998b).  The cell wall of an organism is essential for the survival 
of the cell.  Without the proper addition of the building blocks and maintenance of the 
cell wall, the organism will perish. 
1.3.6.3 Mechanism of Resistance 
Vancomycin-resistant enterococci (VRE) are commonly spread throughout a 
hospital and are difficult to control.  There are a number of vancomycin-resistance 
genes that have been discovered in enterococci.  These include vanA, vanB, vanC 
(Dutka-Malen et al, 1995), vanC2/3 (Kariyama et al, 2000), vanD (Perichon et al, 
1997), vanE (Fines et al, 1999), and vanG (McKessar et al, 2000).  These vancomycin-
resistance genes have seriously compromised the usefulness of vancomycin for 
enterococcal infections.  The products of these genes create an alteration in the 
pentapeptide terminus, prohibiting the glycopeptide from binding to its target 
(Woodford, 1998).  Within the past six years, there have been reports of clinical isolates 
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of S. aureus with intermediate-resistant to resistant phenotypes against vancomycin 
(Hiramatsu et al, 1997a,b; Rotun et al, 1999; Smith et al, 1999b; CDC, 2002a,b; 
Sakoulas et al, 2002; Fridkin, 2003).  Although the mechanism of resistance is 
unknown, the cell wall of S. aureus isolates with intermediate-resistant or resistant 
phenotypes is thicker than the cell wall of susceptible S. aureus or MRSA (Smith et al, 
1999b).  Increasing vancomycin-resistance will decrease the overall efficacy of 
glycopeptides, therefore, studies should be performed to help understand the resistance 
mechanisms. 
1.3.6.4 Side Effects 
Nephrotoxicity and ototoxicity of glycopeptides is a concern, especially when 
administered with an aminoglycoside (Wenk et al, 1984; Gilbert et al, 2002).  
Vancomycin has been associated with an infusion-related reaction called red man 
syndrome (Sivagnanam and Deleu, 2003).  This syndrome typically consists of an 
erythematous rash involving the face, neck, and upper torso.  Glycopeptides have been 
known to cause vomiting and tachycardia (WholeHealthMD.com).  Some frequent side 
effects experienced with glycopeptides include fever, chills, dizziness, and phlebitis 
(Gilbert et al, 2002). 
1.3.7 Aminoglycosides 
1.3.7.1 General Overview 
A review article written by Tolmasky (2000) describes the structure, isolation, 
and development of aminoglycoside agents.  These agents consist of amino sugars 
associated with glycosidic bonds and linked to an aminocyolitol ring.  Some examples 
of aminoglycosides are kanamycin, neomycin, streptomycin, tobramycin (all isolated 
from Streptomyces), and gentamicin and sisomycin (isolated from Micromonospora).  
Amikacin and netilmicin were derived synthetically from kanamycin and sisomycin.  
The most common antimicrobials in this family are gentamicin and tobramycin which 
both have a broad spectrum of activity.  These agents are used to treat serious infections 





1.3.7.2 Mechanism of Action 
Aminoglycosides inhibit protein synthesis by binding irreversibly to the 30S 
ribosomal proteins.  This binding to the 30S ribosomal proteins results in the production 
of aberrant proteins due to misreading of the mRNA and this attachment also causes 
premature release of the ribosome from the mRNA, resulting in protein synthesis 
interruption (Tolmasky, 2000).  The bacterial cell requires properly assembled proteins 
for survival, therefore, the action of aminoglycosides is bactericidal. 
1.3.7.3 Mechanism of Resistance 
Tolmasky (2000) describes three mechanisms by which an organism may 
become resistant to an aminoglycoside.  A mutation in the ribosome-binding site can 
prevent the aminoglycoside from attaching to the 30S ribosomal subunit.  Another 
mechanism of resistance is the decreased uptake of the aminoglycoside accomplished 
by an efflux system.  Resistance can also be due to enzymatic modification (the most 
commonly observed mechanism of resistance to aminoglycosides).  Adenylation, 
acetylation, and phosphorylation of the amino and hydroxyl groups of aminoglycosides 
occur often in bacteria that are resistant to aminoglycosides.     
1.3.7.4 Side Effects 
Aminoglycosides are potentially toxic and this toxicity is dependent on the dose.  
Aminoglycosides may cause nephrotoxicity, ototoxicity, and in rare cases, 
neuromuscular blockade (Gilbert et al, 2002). 
1.3.8 Rifampin 
1.3.8.1 General Overview 
This agent is a member of the ansamycin family of antibiotics.  Rifampin was 
derived from Streptomyces mediterranei (Morris et al, 1993).  Rifampin has shown 
clinical success against Mycobacterium tuberculosis and is also very active against 
staphylococci and streptococci as well as other clinically significant Gram-positive 
organisms (Murray et al, 1998b). 
1.3.8.2 Mechanism of Action 
In a review article written by Morris et al (1993), the authors describe the 
mechanism of action of rifampin.  Rifampin exerts its effects by binding to the DNA-
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dependent RNA polymerase.  The result of this binding is the inhibition of RNA 
synthesis, resulting in cell death.  
1.3.8.3 Mechanism of Resistance 
Resistance develops quickly to rifampin, so this agent is often administered with 
another effective antimicrobial agent.  Almost all isolates resistant to rifampin have a 
mutation in the beta subunit of the RNA polymerase (Ramaswamy and Musser, 1998).  
Gram-negative bacteria are resistant to rifampin intrinsically due to a decreased uptake 
of the drug (Murray et al, 1998b). 
  1.3.8.4 Side Effects 
Common side effects associated with the administration of rifampin include 
heartburn, flatulence, cramps, diarrhea, fever, headache, drowsiness, fatigue, rash, and 
dizziness (RxList.com, 2003b).  Some serious, but rare side effects include hepatitis, 
pseudomembranous colitis, thrombocytopenia, transient leukemia, hemolytic anemia, 
anaphylaxis, and decreased hemoglobin (RxList.com, 2003b). 
1.4 Measurements of Antimicrobial Susceptibility/Resistance 
1.4.1 Emergence of Resistance 
Millions of people suffer from infections caused by antimicrobial resistant 
bacteria.  Often, infections are not entirely cleared by an antibiotic because the bacteria 
undergo a change that allows them to resist the antimicrobial’s effects and continue to 
proliferate in the presence of the agent.  There is great concern about infections caused 
by resistant bacteria because these types of infections may lead to treatment failure in a 
patient, increase overall costs, and result in greater morbidity and mortality among 
patients (Drlica and Schmitz, 2002).   
Gould and MacKenzie (2002) describe many ways in which a resistant 
population may emerge.  A minority population of pre-existing resistant cells may be 
selected out of a heterogeneous population of cells.  A resistant population may also 
proliferate after the selection of induced or random mutations.  This type of resistance is 
called de novo resistance and occurs more often as a stress response as well as when the 
inoculum of the organism is large.  Resistance may develop via the introduction of 
DNA from plasmids, phages, mosaic genes, and transposons which carry resistance 
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determinants.  Bacteria are creative in their ability to develop resistance in a society that 
relies daily on antimicrobial therapy. 
There are many factors that play a role in the emergence of resistant bacteria.  
Studies have shown that the cessation of therapy coincides with a decrease in resistance 
(Smith et al, 1987).  Also, most investigators will agree that increased use of antibiotics 
correlates with increase of resistant organisms present today (Pihlajamaki et al, 2001).  
“Clearly, the most important factor in the emergence of antimicrobial resistance with S. 
pneumoniae, however, is the selective pressure of antimicrobial agents.”  (Doern, 2001).  
Some believe that it is not only the overuse of antibiotics that causes an increase in 
resistance, but also the way in which antimicrobials are used that contribute to the 
emergence of resistance (Drlica and Schmitz, 2002).  Investigators believe that it is 
likely resistant mutants are selected by antimicrobial therapy (Drlica and Schmitz, 
2002).  Also, the inevitable, unintentional exposure of normal flora from both the 
environment and the host to antibiotics is a factor in increasing resistance rates (Gould 
and MacKenzie, 2002).  Also increasing the prevalence of resistant organisms is the use 
of antimicrobial agents in agriculture (Endtz et al, 1991; Gaunt and Piddock, 1996; 
Garau et al, 1999; Smith et al, 1999a; Zhao and Drlica, 2001).  The presence of 
selective pressure increases the possibility of proliferating resistant bacteria.  Another 
factor that may contribute to the increase in resistant organisms is the fact that many 
patients’ immune systems are weak as a result of aging, Human Immunodeficiency 
Virus, radiotherapy, the use of immunosuppressive drugs, etc. (Zhao and Drlica, 2001).  
The weakened immune system reduces the ability to ward off bacteria, thereby allowing 
the resistant bacterial populations to proliferate and possibly infect other susceptible 
patients within a hospital.  It is likely that these factors have contributed to the overall 
increase in resistance observed in bacterial species.      
1.4.2  Minimum Inhibitory Concentration (MIC) Test 
1.4.2.1 Standardized Susceptibility Test 
The standardized method used today to test the susceptibility of an organism to a 
particular agent is the MIC test.  The MIC is the lowest concentration of an 
antimicrobial agent that is required to inhibit the visible growth of an organism when 
compared to the appearance of growth in the control wells (NCCLS, 2001a,b,c,d; 
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Goldstein et al, 2002).  To help determine the proper dosing of an antimicrobial agent, 
the MIC values are considered together with the pharmacokinetic parameters of the 
agent (Drlica and Schmitz, 2002).  The MIC is currently an important parameter used 
for the development of dosing strategies for antimicrobial agents.   
  1.4.2.2 Problems Associated with MIC Testing 
The MIC test has some disadvantages.  A problem with the approach of basing 
dosing strategies on the MIC is that although the MIC is aimed at preventing 
proliferation of susceptible bacteria, it is not aimed at preventing the growth of resistant 
mutants that may be present in a population of cells (Drlica and Schmitz, 2002).  
Indeed, studies with mycobacteria show that the MIC does not reflect the ability of a 
quinolone agent to restrict the selection of resistant mutants (Sindelar et al, 2000; 
Gillespie et al, 2003).  The amount of drug that inhibits visible growth on the MIC 
panel may not be the concentration that will eradicate an infection (Blondeau et al, 
2001).  The MIC may not eliminate all of the organisms and their potential mutants 
(upper portion of Figure 1.1) (Blondeau et al, 2001).  As a result, the widespread use of 
some antimicrobial agents has been correlated with an increase in the number of 
resistant organisms.   
The MIC test examines organisms at approximately 105 cfu/ml and in an 
infected patient, the bacterial numbers may be as high as 109 to 1010 cfu/ml (Gould and 
MacKenzie, 2002).  For many organisms including S. aureus, the spontaneous mutation 
frequency has been reported as one mutation for every 106 to 108 cells (Zhao and Drlica, 
2001).  At inocula exceeding the spontaneous mutation frequency, resistance mutations 
are more likely to occur.  To assess the susceptibility of an infecting isolate, one should 
test that organism at an inoculum exceeding the spontaneous mutation frequency.   
Other concerns with MIC testing are also apparent.  For example, the turbidity 
determinant is subjectively based, the doubling dilutions make results an approximation, 
and the observations are done only once after approximately 18-24 hr (Gould and 
MacKenzie, 2002).  These concerns force one to seek a different approach to 
susceptibility testing of bacteria.  Despite the limitations, MIC testing remains the 
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when exposed to antimicrobial agents at the MIC and MPC. 21
 The global dilemma of increasing resistance may be attributed partly to 
antimicrobial dosing strategies based on MIC testing.  This increase in worldwide 
resistance is not as pronounced as one may expect considering the problems with MIC 
testing.  This may be explained by other factors, such as the immune system which 
plays a significant role in the response to infection (Drlica and Schmitz, 2002).  One 
should still be concerned, however, since the number of immunocompromised patients 
is increasing and one can no longer rely on the immune response to eliminate resistant 
cells that may be present in an infection (Drlica and Schmitz, 2002).  Without a doubt, 
the traditional low-dose antimicrobial therapy, which was thought to have clinical 
efficacy, minimal toxicity, and lower cost, has exacerbated resistance problems 
(Blondeau et al, 2002b; Gould and MacKenzie, 2002).  
 As bacteria become increasingly resistant to the antimicrobials in use today, 
healthcare professionals are becoming more desperate to prevent this emerging 
resistance.  It was originally thought that resistant mutants had a fitness deficit, 
however, there is evidence indicating that resistant mutants are just as hearty as 
susceptible cells (Gillespie et al, 2002).  This finding raises concern as resistant mutants 
are able to withstand more extreme environments than originally thought.  New 
treatment strategies to accompany antimicrobials should be considered to help stop the 
selection of resistant subpopulations and, hence, maintain the clinical efficacy of agents 
(Blondeau et al, 2001, 2002b). 
1.4.3 Mutant-Prevention Concentration (MPC) 
  1.4.3.1 Theory 
Because of the recognized problems associated with MIC testing, a novel 
measurement of susceptibility/resistance has been developed.  The mutant-prevention 
concentration (MPC) is based on the concept that at a certain concentration of drug, 
emergence of resistant organisms will be prevented due to the killing of all organisms, 
including the potential mutants, by this increased concentration.  Concentrations 
currently used for various infections destroy the majority of susceptible pathogens, but 
at the same time are often the very concentrations required to select a resistant pathogen 
(Zhao and Drlica, 2001).  Instead of testing the organism at 105 cfu/ml, as the MIC test 
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is performed, the MPC approach utilizes organisms at an inoculum of ≥109 cfu/ml.  By 
increasing the inoculum, an environment conducive to the selection and proliferation of 
resistant mutants is created (Zhao and Drlica, 2001).  Large bacterial inocula often exist 
as heterogeneous populations with a dominant phenotype mixed with mutant 
phenotypes (Drlica and Schmitz, 2002).  The MPC has been described as a “…drug 
concentration threshold above which bacterial cells require the presence of two or more 
resistance mutations for growth.” (Drlica and Schmitz, 2002).  This is, indeed, true in 
the case of the fluoroquinolone and des-quinolone agents.  For the quinolones, the 
spontaneous mutation frequency is approximately one mutation for every 107 cells 
(Zhao and Drlica, 2001).  The MPC tests organisms at inocula exceeding this number of 
cells.  Susceptibility testing above this frequency gives a concentration of drug above 
which no mutant should grow because a double mutation (requiring 107 X 107 = 1014 
bacterial cells) is extremely rare in nature and in human infectious diseases as patients 
would not have bacterial loads of this magnitude.  The MPC is defined as the MIC of 
the least susceptible single cell mutant (Zhao et al, 2003).  The MPC is, therefore, a 
concentration of drug that will prevent the growth of first-step resistant mutants present 
in a heterogeneous population of bacterial cells (lower portion of Figure 1.1). 
Most of the relevant MPC data have been obtained with fluoroquinolones 
(Blondeau et al, 2001; Zhao and Drlica, 2001; Drlica and Schmitz, 2002; Hansen et al, 
2003; Zhao et al, 2003).  Non-quinolone agents have not been thoroughly studied with 
the MPC approach.  It is important to test different families of antimicrobial agents to 
determine whether an increased inoculum plus the selective pressure of an agent have 
any effect on the concentration of drug required to prevent the growth of entire bacterial 
populations. 
  1.4.3.2 Application 
The MPC values may be used in a similar way to the MIC values where the 
values are combined with the pharmacokinetic properties of antimicrobial agents and 
together new dosing strategies may be developed.  The difference in the approach with 
the MPC values is that the new dosing strategies will be aimed at preventing resistance 
by killing both susceptible and resistant bacterial cells, whereas currently with the MIC 
values, dosing strategies may actually encourage growth of resistant subpopulations 
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(refer to Figure 1.1).  The comparison of MIC and MPC values for an isolate, plus the 
plotting of these values on the pharmacokinetic curve of an antimicrobial agent, could 
provide additional information as to the appropriate dosing strategy of an agent.  
Therefore, the MPC may be an important parameter when considering prevention of 
resistance based on dosing strategies.  To date, however, this strategy has been most 
extensively studied with fluoroquinolone agents. 
 1.4.4 Mutant-Selection Window (MSW) 
  1.4.4.1 Definition/Relationship to MIC and MPC Values 
Following from the MPC, the concept of the mutant-selection window (MSW) 
was developed.  The MSW is defined by the drug concentrations between the MIC and 
the MPC and includes the concentrations of drug that enrich resistant mutants (Zhao 
and Drlica, 2001).  It has been previously shown that a S. aureus population can reduce 
its susceptibility to an agent while in the presence of drug concentrations that are within 
the MSW (Firsov et al, 2003).  Below the MIC, no mutant is selected because the 
selective pressure is insufficient as neither susceptible nor first-step resistant cells will 
be inhibited (Blondeau, 2003).  Also, no mutant should grow above the MPC because 
that would require two mutations which, as stated previously in section 1.4.3.1, is rare.  
Within the MSW, susceptible cells are inhibited, however, resistant subpopulations may 
be selectively amplified (Blondeau, 2003).   
  1.4.4.2 Clinical Application 
Current pharmacodynamic strategies result in drug concentrations that fall 
within the MSW for some antimicrobial compounds.  The ultimate goal should be to 
avoid the MSW or to administer agents for as short time as possible while in the 
window (Zhao and Drlica, 2001).  Because the MSW is measurable, antimicrobial 
agents can be compared to determine compounds that are better suited for 
administration at the MPC or above (Zhao and Drlica, 2001).  Compounds better suited 
for therapy include those with a narrow or closed window (where the MIC is equal to 
the MPC).  One may also avoid serum/tissue concentrations in the MSW by utilizing 
combination therapy or by adjusting the dosage regimen (Zhao and Drlica, 2001).  The 
ideal dose for patients would be above the MPC, providing that it is clinically 
achievable, sustainable, and not likely to induce unfavorable toxicities (Zhao and 
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Drlica, 2001).  During therapy, if the serum/tissue drug concentration is maintained 
above the MPC concentration, very few or no resistant mutants will be selectively 
amplified (Drlica and Schmitz, 2002).  Thus, the MSW and, hence, MPC data, may be 
important when treating infections with antimicrobial agents against organisms with the 
potential to become resistant. 
1.5 Summary 
S. aureus is a problematic organism causing worldwide morbidity and mortality. 
As well, S. aureus rapidly develops resistance to antimicrobial agents.  This, in turn, has 
compromised the use of many antimicrobial agents.  Current dosing strategies may 
encourage the development of resistance.  As new and effective agents are being 
developed, new dosing strategies should accompany these agents to prevent resistance 
to these novel agents.   
The MPC is a novel test utilizing large bacterial populations with the presence 
of a selective antimicrobial agent.  The MPC data may be clinically significant when 
treating patients with a S. aureus infection.   As the prevalence of resistance increases, it 
is important that antimicrobial agents be considered for their propensity to selectively 
enrich resistant subpopulations (Zhao et al, 2003).  The MPC data may be used to help 
determine agents less likely to select for resistant subpopulations.  In addition, the MPC 
test provides a measurement of drug concentration required to eliminate first-step 
resistant mutants (Zhao et al, 2003).  The objective is to use compounds that have low 
and narrow MSWs and that can be administered safely above the MPC (Zhao and 
Drlica, 2001).   However, because dosing regimens for currently used agents were 
developed for achieving concentrations above the MIC, few of these agents are likely 
appropriate for maintaining concentrations above the MPC (Zhao and Drlica, 2002).  
The MPC is, therefore, useful in the development of new dosing strategies for novel 
agents or in helping to determine agents less likely to select for resistance based on the 
amount of time the drug concentration is within the MSW.   
Clearly, it is important to determine if resistant subpopulations exist in wild type 
susceptible populations (as determined by MIC testing).  Should such populations be 
found, the potential impact of inadvertently selecting for these resistant subpopulations 
with improper antimicrobial dosing strategies may be devastating for infected patients 
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on antimicrobial therapy.  One may reduce the likelihood of selecting for resistance by 
treating patients with the proper dosage of drug and this dosage may be acquired with 
the help of the MPC data. 
1.6 Objectives 
The MPC approach has been shown to be significant for evaluating the 
emergence of resistance in S. pneumoniae organisms (Blondeau et al, 2001; Hansen et 
al, 2001; Tillotson et al, 2001; Blondeau et al, 2002b; Blondeau, 2003).  The hypothesis 
I based my research upon is that the MPC approach is also important for evaluating the 
emergence of resistance in S. aureus organisms.  As well, the MPC may provide 
valuable insight as to dosing strategies necessary to restrict the selection of resistant S. 
aureus subpopulations. 
My first objective was to determine MPC values for MRSA and methicillin-
susceptible S. aureus (MSSA) isolates to different families of antimicrobial agents.  
From these data, one may compare the in vitro potency of the agents using MPC 
values.  As well, one may compare the behavior of MSSA and MRSA isolates to 
different antimicrobial agents.  Using MIC and MPC data, one may establish the MSW 
and, hence, determine agents least likely to select for resistant subpopulations. 
My second objective was to study the susceptibility behavior of sequential S. 
aureus isolates.  Scientists hypothesize that throughout antimicrobial therapy a patient 
may develop an infection that is resistant as a result of selective amplification of a 
resistant subpopulation.  There are few reports proving that treatment with an 
antimicrobial agent may select resistant mutants, in vivo (Davidson et al, 2002; 
Anderson et al, 2003).  MIC or MPC changes among multiple sequential organisms 
isolated from patients undergoing antimicrobial therapy was studied.  Studies such as 
these may provide evidence that resistant subpopulations may proliferate as a result of 





2.0 MATERIALS AND METHODS 
2.1 Standard Laboratory Methods 
 2.1.1 Isolate Collection and Identification 
The S. aureus isolates used in this study were collected through the Clinical 
Microbiology Department at Royal University Hospital (RUH), Saskatoon, 
Saskatchewan, Canada.  Individual isolates were obtained from February (2001) to 
September (2001), while sequential isolates were obtained from October (2001) to 
March (2002).  Identification of S. aureus was in accordance with the Manual of 
Clinical Microbiology (Murray et al, 2003) determined by Latex agglutination 
(Staphaurex™) as recommended by Remel, Incorporated, 2002.  The MRSA isolates 
were determined as such by the Oxacillin Screen Plate (Murray et al, 2003) or by PCR 
analysis of the mecA determinant gene (Predari et al, 1991). 
S. pneumoniae isolates were collected between May (2002) and December 
(2002).  Identification of S. pneumoniae was in accordance with the Manual of Clinical 
Microbiology (Murray et al, 2003) determined by traditional methods, including 
catalase testing, bile solubility, and optochin sensitivity.  A novel method using the 
Slidex Pneumo-Kit by bioMerieux (in accordance with the instructions provided by the 
supplier) was also used to identify S. pneumoniae isolates. 
 2.1.2 Storage of the Bacterial Isolates 
The isolates were obtained from Tryptic Soy Agar (TSA) slants (in house), TSA 
plates containing 5% sheep blood, and from frozen skim milk.  Organisms identified as 
S. aureus or S. pneumoniae were streaked for isolated colonies onto a TSA plate 
containing 5% sheep blood and incubated in ambient air at 35-37˚C for approximately 
24 hr.  One or two isolated colonies were selected from the TSA plate with a sterile 
wooden applicator stick and inoculated into 1.2 ml Corning cryovials containing 0.5 ml 




 2.1.3   Susceptibility Testing 
There are a variety of methods by which to test the susceptibility of an isolate.  
The most common methods used today in clinical laboratories are the disk diffusion test 
(Kirby-Bauer), E-test, agar dilution test, and broth microdilution (Andersen, 2000).  
Broth microdilution and E-tests were performed in this study.  Most healthcare 
professionals view broth microdilution as an accepted, reliable, and well-standardized 
method for susceptibility testing. 
  2.1.3.1 Broth Microdilution 
MIC values were determined from the broth microdilution test in accordance 
with NCCLS guidelines (NCCLS, 2001a,b,c,d).  Ninety-six well flat bottom microtitre 
plates were filled with 100 µl of Mueller Hinton Broth (MHB) in each well of columns 
2-12.  Antimicrobial agent was serially diluted across the plate with column 1 
containing the highest drug concentration and column 12 receiving no drug (growth 
control).  Each isolate was standardized to a 0.5 McFarland suspension using a 
Colorimeter (~1.0 X 108 cfu/ml).  The bacterial suspension was then diluted 1/100 with 
MHB (~1.0 X 106 cfu/ml).  One hundred µl of diluted cells were added to each well on 
the plate resulting in a final volume of 200 µl.  Purity of the bacterial suspension was 
confirmed by plating each sample onto a fresh TSA plate containing 5% sheep blood.  
The plates (both microtitre and blood agar) were incubated in ambient air at 35-37˚C for 
16-20 hr.   The growth control wells (column 12) were examined prior to MIC 
determination to ensure organism viability.  Also, the purity plates were examined prior 
to MIC determination to ensure the culture remained pure throughout the experiment.  
The American Type Culture Collection (ATCC) strain, S. aureus 29213, was used as a 
control to confirm accuracy of each MIC test (ATCC, Manassas, VA 20108 U.S.A).  
MIC control ranges for isolate 29213 are listed in Appendix D for the various 
antimicrobials that were tested by broth microdilution.  The MIC value was recorded as 
the lowest drug concentration at which there was no visible growth of the organism.  
The antibiotics tested by broth microdilution included: azithromycin, cefazolin, 
cefotaxime, cefuroxime, cephalexin, cloxacillin, ciprofloxacin, garenoxacin, 
gatifloxacin, gemifloxacin, gentamicin, levofloxacin, moxifloxacin, rifampin, 
piperacillin/tazobactam, and vancomycin. 
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Broth microdilution for S. pneumoniae isolates was done similar to that 
described for S. aureus isolates.  However, Todd Hewitt Broth (THB) was used, as was 
the S. pneumoniae control strain, ATCC 49619.  All plates were incubated at 35-37°C 
in 5% CO2 and 95% ambient air for 16-20 hr.  Agents tested with S. pneumoniae by 
microdilution include azithromycin, clarithromycin, and erythromycin.  Control ranges 
of S. pneumoniae 49619 for azithromycin, clarithromycin, and erythromycin are listed 
in Appendix D. 
   2.1.3.2 E-Test 
E-tests were also performed to determine the clindamycin MIC value of isolates.  
E-test strips contain high antimicrobial concentrations at one end of the strip with 
decreasing drug concentrations proceeding towards the opposite end of the strip.  Each 
organism was standardized to a 0.5 McFarland inoculum.  S. aureus ATCC 29213 was 
used as a control to confirm the accuracy of the resulting MIC values.  Sterile swabs 
were used to transfer each isolate from the 0.5 McFarland suspensions to TSA plates 
containing 5% sheep blood.  Using forceps, E-test strips were carefully placed in the 
middle of each plate.  The 0.5 McFarland suspensions of bacteria were tested for purity 
by placing sterile wooden applicator sticks into the tubes and streaking for isolated 
colonies onto TSA plates containing 5% sheep blood.  The plates were then incubated at 
35-37°C in ambient air for 18-24 hr.  Results were recorded according to the 
corresponding location on the strip where the growth of the organism was inhibited.  
MIC values are the lowest drug concentration values where no bacterial growth 
occurred.     
2.2 Mutant-Prevention Concentration (MPC) 
The MPC values for S. aureus were determined with a protocol developed as 
part of this thesis work (Metzler et al, in press).  The protocol was based on a MPC 
protocol published earlier for S. pneumoniae (Blondeau et al, 2001).  S. aureus ATCC 
29213 was used as a control strain.  
 2.2.1 Inoculum 
Each S. aureus isolate was subcultured from thawed skim milk onto TSA plates 
containing 5% sheep blood using a sterile wooden applicator stick and incubated in 
ambient air at 35-37˚C for approximately 24 hr.  A sterile swab was used to collect as 
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much bacteria as possible from each plate and then sub-cultured onto three fresh TSA 
plates containing 5% sheep blood (two plates were entirely covered with the bacteria 
and one plate was streaked for isolated colonies).  These plates were then incubated in 
ambient air for approximately 24 hr.  Sterile swabs were used to transfer the contents of 
the plates to sterile bottles containing 100 ml of MHB.  One hundred µl were taken 
from bottles and streaked onto plates containing various concentrations of antimicrobial 
agent.  Spectrophotometer readings were recorded for each sample by adding 2 ml of 
the inoculum to a clean cuvette and placing it in the spectrophotometer.  Organisms 
with a spectrophotometer reading <1.0 were re-grown until an inoculum with a 
spectrophotometer reading of ≥1.0 was observed.  Previously, it was determined that 
readings ≥1.0 resulted in inocula of ≥109 cfu/ml for S. aureus organisms (in house 
observation).  All plates were incubated for 48 hr in ambient air (35-37˚C) and screened 
for growth at both 24 and 48 hr.  The MPC was recorded as the lowest drug 
concentration that had no visible bacterial growth on the plate. 
The MPC procedure for S. pneumoniae isolates varied slightly from the MPC 
procedure used for S. aureus isolates.  S. pneumoniae ATCC 49619 was tested in each 
MPC test performed with S. pneumoniae isolates.  The MPC protocol used for S. 
pneumoniae followed the format described in Blondeau et al, 2001.  Briefly, from a 
fresh overnight culture, S. pneumoniae isolates were plated onto eight plates and 
incubated at 35-37°C in 5% CO2 and 95% atmospheric air for 24 hr before inoculation 
into 500 ml of THB.  After a 24 hr incubation of the 500 ml inoculum at 35-37°C in 5% 
CO2 and 95% atmospheric air, each isolate was centrifuged in an Avanti J-E centrifuge 
(Beckman Coulter) at 5000 X g for 30 min.  Pellets were resuspended in 3 ml of THB 
and 200 µl were plated onto TSA plates containing various concentrations of drug.  
Plates were incubated in 5% CO2 and 95% atmospheric air at 35-37°C for 48 hr with 
observations recorded at both 24 and 48 hr.   
  2.2.2 Antimicrobial Plates 
 Initial concentrations used in the experiment consist of one doubling dilution 
below the MIC, the MIC, and five doubling dilutions above the MIC.  Upon repeat 
testing, the range of drug concentrations varied depending on the behavior of the 
organism (if the organism did not grow on any antimicrobial plates, the MIC was 
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repeated and the MPC range was lowered; if the organism grew at the highest drug 
concentration plate, the MPC range was extended and the experiment was repeated at a 
higher range).  Antimicrobial agents were prepared as described in Appendix C.  TSA 
was prepared from powder form according to the manufacturer’s descriptions as 
described in Appendix A.  The agar was kept at 55˚C in a water bath until it was ready 
to pour.  To determine the amount of agent to add, I used the following formula: 
 
C1V1=C2V2                     (2.1)
    
Where C1 was equal to the stock concentration of antimicrobial agent, C2 was equal to 
the desired concentration, V2 was equal to the total volume, and V1 was equal to the 
volume of antimicrobial agent that must be added to obtain the desired drug 
concentration.  Approximately 20 ml of agar containing drug were poured into each 
sterile petri plate and each plate was labeled appropriately with the name of the agent 
and its concentration.  Addition of 5% sheep blood to the TSA was necessary for the 
proper growth of S. pneumoniae isolates.   
 2.2.3 Viable Counts 
Viable counts were performed on selected organisms for each round of MPC tests.  
Dilutions of 10-7, 10-8, and 10-9 were made from the bacterial suspension and 100 µl of 
each dilution were plated onto triplicate TSA plates containing 5% sheep blood.  The 
plates were incubated for 24 hr at 35-37°C in ambient air.  Colony counts were 
performed on each plate.  Calculations were then performed to determine colony 
forming units per ml.  This was done by multiplying the average of three plates by the 
reciprocal of the dilution factor and then multiplying by 10 for results in colony forming 
units per ml (cfu/ml). 
2.3 Characterization of Bacterial Isolates 
 2.3.1 Polymerase Chain Reaction (PCR) 
  2.3.1.1 Primer Preparation 
Primers used in this study are listed in Table 2.1.  Each primer, including the 
upstream and the downstream primer, were dissolved at a concentration of 100 µM by 
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vanA1 Upstream 5' GGGAAAACGACAATTGC 3' 53 47 732 
 Downstream 5' GTACAATGCGGCCGTTA 3' 56 52   
vanB1 Upstream 5' ATGGGAAGCCGATAGTG 3' 58 52 635 
  Downstream 5' GATTTCGTTCCTCGACC 3' 73 52   
vanC1 Upstream 5' GGTATCAAGGAAACCTC 3' 54 47 822 
  Downstream 5' CTTCCGCCATCATAGCT 3' 55 52   
vanC2/C32 Upstream 5' CGGGGAAGATGGCAGTAT 3' 45 56 484 
  Downstream 5' CGCAGGGACGGTGATTTT 3' 36 56   
vanD3 Upstream 5' TAAGGCGCTTGCATATACCG 3' 60 50 461 
  Downstream 5' TGCAGCCAAGTACCGGTAA 3' 49 50   
vanE4 Upstream 5' TGTGGTATCGGAGCTGCAG 3' 68 58 513 
  Downstream 5' GTCGATTCTCGCTAATCC 3' 62 50   
vanG5 Upstream 5' CGGTTGTGCCGTACTTGGC 3' 45 63 810 
  Downstream 5' GGGTAAAGCCATAGTCTGGGGC 3' 55 59   
ermA6 Upstream 5' GTTCAAGAACAATCAATACAGAG 3' 51 35 421 
  Downstream 5' GGATCAGGAAAAGGACATTTTAC 3' 51 39   
ermB7 Upstream 5' GAAAAGGTACTAAACCAAATA 3' 48 29 639 
  Downstream 5' AGTAACGGTACTTAAATTGTTTAC 3' 64 29   
ermC6 Upstream 5' GCTAATATTGTTTAAATCGTCAATTCC 3' 61 30 572 
  Downstream 5' GGATCAGGAAAAGGACATTTTAC 3' 64 39   
mefA7 Upstream 5' ACTATCATTAATCACTAGTGC 3' 48 33 348 
  Downstream 5' TTCTTCTGGTACTAAAAGTGG 3' 40 38   
msrA/msrB8  Upstream 5' GCAAATGGTGTAGGTAAGACAACT 3' 52 42 400 
 Downstream 5' ATCATGTGATGTAAACAAAAT 3' 46 24  
mecA9 Upstream 5’ GGGATCATAGCGTCATTATTC 3’ 85 43 526 
 Downstream 5’ AACGATTGTGACACGATAGCC 3’ 51 48  
 
1Dutka-Malen et al (1995) 
2Kariyama et al (2000) 
3Perichon et al (1997) 
4Fines et al (1999) 
5McKessar et al (2000) 
6Lim et al (2002) 
7Hoban et al (2001) 
8Wondrack et al (1996) 
9Predari et al (1991) 
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adding the appropriate volume of ½TE Buffer (preparation of buffer described in 
Appendix A) to dried primer which had been stored at -20ºC.  Each tube was then 
vortexed.  Dissolved primer was diluted to 20 µM with ½TE Buffer.  Equal volumes of 
the upstream and the downstream primer were then added to a single tube and vortexed.  
Primer solutions were stored at -20ºC. 
   2.3.1.2 Setting up the PCR Reaction Tubes 
Bacterial isolates were thawed and plated on a TSA plate (containing 5% sheep 
blood) as described in section 2.1.2.  From the blood plate, a visible loop of bacteria 
was added to 100 µl of InstaGene™ Matrix.  For isolates tested for van genes, 10 µl of 
specimen were taken directly from thawed saline and added to 100 µl of InstaGene™ 
Matrix.  Each specimen was boiled for 10-12 min and then centrifuged for ~45 sec at 
16,000 X g.  Three µl of primer were added to each tube of PuReTaq Ready-To-Go 
PCR Beads.  A total of 19.5 µl of sterile distilled water were added to each PCR 
reaction tube.  Finally, 2.5 µl of supernatant from each specimen were added to the 
appropriate PCR reaction tubes resulting in a final volume of 25 µl.  Each PCR reaction 
tube was vortexed vigorously until the PuReTaq Ready-To-Go PCR bead was 
completely dissolved.  During preparation of samples, latex gloves were worn at all 
times. 
   2.3.1.3 Thermocycler Settings  
 Settings for the thermocycler varied, depending on the primers that were used.  
Table 2.2 displays the thermocycler settings that were used for each primer set.  For 
ermA, ermC, and msrA/msrB, two sets of parameters were used for PCR.  After the final 
extension for each set of parameters, the samples were kept at 4°C until electrophoresis. 
 2.3.1.4 Agarose Gel Electrophoresis 
PCR samples were run on a 1% agarose gel prepared as described in Appendix 
A.  Six µl of Tracking Dye were added to each PCR reaction tube.  For the marker, 2 µl 
of a 123 bp ladder were added to 12 µl of sterile distilled water and 4 µl of Tracking 
Dye.  Each tube was gently mixed.  Approximately 20 µl were loaded into designated 





Table 2.2: Thermocycler conditions for the primers used in this study. 
 
Primers Initial Denaturation Denaturation Annealing Elongation # Cycles Final Elongation
Temp1 Time (min) Temp Time (sec) Temp Time (sec) Temp Time (sec) Temp Time (min)
ermA 2 94 2 94 60 53 60 72 60 30 72 10
ermA 3 95 5 94 30 54 30 72 60 35 72 5
ermB 2 94 2 94 60 53 60 72 60 30 72 10
ermC 2 94 2 94 60 53 60 72 60 30 72 10
ermC 3 95 5 94 30 54 30 72 60 35 72 5
mefA 2 94 2 94 60 53 60 72 60 30 72 10
msrA/msrB 2 94 2 94 60 53 60 72 60 30 72 10
msrA /msrB 4 95 3 93 30 55 120 72 90 35 72 10
mecA 5 95 4 94 35 56 35 72 40 35 72 6
vanA 6 94 2 94 1 54 1 72 60 30 72 10
vanB 6 94 2 94 1 54 1 72 60 30 72 10
vanC 6 94 2 94 1 54 1 72 60 30 72 10
vanC2/C3 7 94 5 94 30 53 30 72 30 35 72 10
vanD 7 94 5 94 30 53 30 72 30 35 72 10
vanE 7 94 5 94 30 53 30 72 30 35 72 10
vanG 7 94 5 94 30 53 30 72 30 35 72 10
1Temp=Temperature
2Thermocycler conditions derived from Hoban et al  (2001)
3Thermocycler conditions derived from Lim et al  (2002)
4Thermocycler conditions derived from Wondrack et al  (1996)
5Thermocycler conditions derived from Predari et al  (1991)
6Thermocycler conditions derived from Dutka-Malen et al (1995)





  2.3.2 Electron Microscopy (EM) 
 2.3.2.1 Preparation of Samples  
 The S. aureus sample for electron microscopy (EM) was grown up continually 
under the selective pressure of the antimicrobial agent.  Isolate #41m was recovered 
from an MPC agar plate containing 4 µg/ml of vancomycin.  MHB containing 4 µg/ml 
of vancomycin was then inoculated with #41m.  The inoculated tube was placed in a 
shaking water bath at 37°C for 48 hr.  An additional tube containing MHB was 
inoculated with #41 (parent isolate of #41m) and was then placed in the shaking water 
bath at 37°C for 24 hr.  Five hundred µl were taken out of each tube, added to 1.5 ml 
eppendorf tubes, and the cells were spun down at 16,000 X g for 1 min.  Broth was 
decanted with a Pasteur pipette and 300 µl of 2% Glutaraldehyde were quickly added to 
each tube.   
   2.3.2.2 Saskatoon Health Region Protocol 
The remaining steps required for EM were performed by Karen Slattery 
(Department of Pathology, Saskatoon Health Region, SHR).  Briefly, the samples were 
fixed for 1 hr in 2% glutaraldehyde and then were washed twice (15 min each time) in 
0.1M sodium cacodylate buffer.  The samples were then post-fixed in 2% osmium 
tetroxide for 1 hr.  Dehydration of the samples was carried out through three 5 min 
rinses in increasing concentrations of ethanol (50, 70, and 95%).  The samples then 
went through three 5 min rinses of propylene oxide and followed by a 50:50 mixture of 
propylene oxide and epon araldite, the embedding media.  The samples were then 
embedded in pure epon araldite in BEEM capsules and hardened overnight at 80°C.  
The blocks were sectioned at 1 µm using a Reichert ULTRACUT E then stained with 
1% Toluidine Blue, cover slipped and screened using a light microscope.  Ultra thin 
sections were cut at 60-90 nm then stained with 3% uranyl acetate and Reynold’s lead 
citrate.  The samples were examined using a Zeiss EM 10C electron microscope and 
micrographs were printed of areas of interest. 
  2.3.2.3 EM Analysis 
 Various fields of view containing many cells were photographed at 40,000X.  
Blind measurements were taken at the north, east, south, and west sides of each cell 
wall, where visible.  The prints were 2.4X the negative, therefore, the magnification was 
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multiplied by 2.4 to result in a final magnification of 96,000X.  The initial 
measurements were recorded in millimeters and were divided by 96,000 and multiplied 
by 1000 to convert the results to µm.  From there, the measurements were converted to 
angstroms by multiplying by 10,000.  Statistical analysis was performed between cell 
wall measurements taken from the parent susceptible population (#41) and from the 
MPC-recovered population (#41m). 
    2.3.2.3.1 Statistical Analysis 
 A right-tailed hypothesis test according to Mann (1998b) was set up to 
determine if the mean of the cell wall measurements for #41m was significantly greater 
than the mean of cell wall measurements for #41.  The average of both population sets 
and standard deviations were determined.  The calculation used for standard deviation 
was as follows:  
 
 s = √s2               (2.2) 
 
 s2 = ∑(x-µ)2          (2.3) 
                      n-1 
 
Where ‘x’ was equal to the measurement of the cell wall, ‘µ’ was equal to the mean of 
the cell wall size for the sample population, and ‘n’ was equal to the number of 
measurements taken for the sample population.  The number of measurements for each 
population was ≥30, therefore, the normal distribution curve was used.  The critical 
value (Zc) is dependent on the significance level (α) of the test.  The sample test value 
(Zt) was calculated as follows: 
 
Zt = µ#41m-µ#41        (2.4) 
           sµ#41-µ#41m 
 
Where sµ#41-µ#41m= √   (s#41)2 + (s#41m)2      (2.5) 
                                        n#41        n#41m    
 
If the test value exceeds the critical value, I reject the null hypothesis (Ho) which stated 
that the cell wall thicknesses are not significantly different.   
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 2.3.3 Sequencing 
  2.3.3.1 Preparation From a Gel Sample 
A PCR-amplified DNA fragment was taken from a gel and prepared for 
sequencing.  This was done by cutting out the desired band from the gel while using an 
ultraviolet light.  The band was placed in a tube with 500 µl of sterile distilled water and 
kept at 4°C overnight.  Two PCR beads (described in section 2.3.1.2) were then placed 
in a single tube.  A total of 6 µl of primer were added to the tube, plus 33 µl of sterile 
distilled water.  After vigorous vortexing, 5 µl of the overnight sample containing the 
gel were added to the tube.   
Also, a sample was prepared from a fresh overnight culture.  This was done by 
boiling the cells for 10 min from a fresh culture.  Then, 5 µl of sample were placed into 
a tube containing two PuReTaq Ready-To-Go PCR beads.  As mentioned above, 6 µl of 
primer plus 33 µl of sterile distilled water were also added to the tube. 
The samples (both the sample from a gel and the sample from a fresh culture) 
were placed in the thermocycler and the settings used were those that were used for the 
PCR experiment.  After the thermocycler had completed its cycles, 12.5 µl of sample, 
plus 6 µl of tracking dye were loaded into the gel.  Leftover sample was saved for 
further preparation for sequencing with the Wizard Kit.  The samples were then run on a 
1% agarose gel for 30 min at 117 volts.  The gel was then analyzed with the Gel-Doc 
1000 Illuminator system to ensure purity as indicated by a distinct, single band. 
  2.3.3.2 Wizard Kit Protocol 
The protocol used was based on the directions supplied by the manufacturer.  A 
total of 100 µl of Wizard Direct Purification Buffer™ were added to the sample and 
vortexed briefly.  One ml of Wizard Purification Resin™ was added to the tube and the 
tube was vortexed briefly three times during a 1 min period.  The sample was then put 
through a mini column into an empty tube.  Following the sample, two ml of 80% 
isopropanol were put through the mini column.  The sample was then centrifuged for 2 
min.  Fifty µl of water were added to the sample.  After 1 min, the sample was 
centrifuged for 20-60 sec.  The sample was then quantified.  This was done by running 
10 µl of the sample in one lane and a mass ladder with known DNA concentrations in a 
neighboring lane of the gel.  A visual comparison of the intensity of the sample band to 
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the intensities of the known concentrations of the bands in the mass ladder was 
performed. 
  2.3.3.3 Sequencing Procedure 
The sequencing procedure was performed by Jennifer Beck in the DNA 
Sequencing Laboratory at the National Research Council.  An upstream primer was sent 
at a concentration of 3.2 pmole/µl along with the sample at a concentration of 10 ng/µl. 
 2.3.4 Pulsed Field Gel Electrophoresis (PFGE) 
  2.3.4.1 Preparation of Samples 
A few colonies from a pure culture of each S. aureus isolate were chosen from a 
TSA plate containing 5% sheep blood and inoculated into 5 ml of MHB.  The samples 
were then placed in a shaking water bath at 37°C for 16-18 hr.  Each sample was then 
centrifuged at 16,000 X g for 1 min.  Each pellet was resuspended in 150 µl of Cell 
Suspension Buffer (CSB) (described in Appendix A). 
  2.3.4.2 Casting Plugs 
Preparation of a 2% low melting point (LMP) agarose in CSB was performed 
for the casting plugs (Appendix A).  Two µl of Lysostaphin at 1 mg/ml were added to 
each tube followed by the immediate addition of 150 µl of 2% LMP agarose.  The tube 
was mixed well and then the contents were added to the casting mold.  The casting 
plugs were left to solidify for 30 min at room temperature and 30 min at 4°C. 
  2.3.4.3 Lysis of Cells in LMP Agarose 
Lysis Buffer (Appendix A) was made up fresh and 750 µl were added to a new 
tube for each sample.  The plugs were gently transferred from the mold to their 
corresponding labeled tube containing the Lysis Buffer.  Each plug was then incubated 
at 37°C for 1 hr.  The Lysis Buffer was then aspirated off with a 1 ml pipette.  Plugs 
were then transferred to microfuge tubes.  Proteinase K (20 mg/ml) was diluted in 
Proteinase K Buffer (final concentration equaling 50 µg/ml) and 750 µl of this solution 
were added to each microfuge tube containing the plugs.  The tubes were then incubated 
in a shaking water bath at 50°C for 0.5 hr to overnight. 
  2.3.4.4 Washing LMP Plugs 
After removing the tubes from the 50°C water bath, the Proteinase K solution 
was aspirated off.  The plugs were rinsed once with 1 ml of Wash Buffer (Appendix A).  
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Three additional washes with 1 ml of fresh Wash Buffer each time was performed for at 
least 30 min for each wash.  The washes were conducted at room temperature.  The 
Wash Buffer was removed after the final wash and 1 ml of fresh Wash Buffer was 
added for long term storage of the plugs. 
  2.3.4.5 Restriction Enzyme Digestion of LMP Plugs 
Approximately one third of each plug was cut on a clean surface and placed into 
a new 1.5 ml microfuge tube.  Four hundred and fifty µl of 1X Buffer A were added to 
each tube and the contents of the tube were allowed to sit for 10 min to equilibrate each 
sample.  SmaI was used to restrict the DNA.  A total of 25 Units were used per sample.  
The volume required was calculated as follows: 
 
Total enzyme required (Units) = Volume required     (2.6) 
SmaI Concentration (Units/µl) 
 
Buffer A was removed from the plugs and 150 µl of Buffer A/SmaI mixture were added 
to each tube.  The tubes were then incubated at 25°C overnight. 
  2.3.4.6 Casting Agarose Gel 
The samples were run on a 1% pulsed field agarose gel prepared as described in 
Appendix A.  Approximately 2 L of 0.5X TBE was added to the Contour Clamped 
Homogenous Electric Field (CHEF) chamber.  The cooling module was set at 14°C and 
the pump was turned on to allow the buffer to cool.  The enzyme/buffer solution was 
aspirated from each sample and the plugs were melted in a water bath set at 65-70°C for 
10-15 min.  A Lambda DNA Ladder was run in at least one lane and was used to help 
determine sizes of the resulting bands.  Thirty µl of each sample were loaded into the 
designated lanes.  The gel was then placed into the electrophoresis chamber.  
Conditions for electrophoresis are given in Appendix B. 
  2.3.4.7 Staining and Documentation of the Gel 
After 18 hr under pulsed field conditions, the gel was placed into a container 
with ethidium bromide (ETBr) (see Appendix A).  The gel was stained for 20-30 min on 
a slowly rocking surface while prohibiting the exposure of the gel to light.  The ETBr 
solution was then drained and destaining was performed by adding 500 ml of distilled 
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water to the container and placing it back on the rocking surface, again covered, for 30 
min.  The gel was analyzed on the Gel Doc 1000 Illuminator (See Appendix E). 
2.4 Miscellaneous Experiments 
 2.4.1 Overcrowding 
 The overcrowding experiment was performed with a protocol similar to the 
MPC procedure for S. aureus described in section 2.2.  However, in the overcrowding 
experiment, volumes of inoculum to be added to the plates varied between 25 µl and 2 
ml.  For each different volume of inoculum, seven plates containing various drug 
concentrations were used.  Viable counts were performed and cfu added to each plate 
were determined by dividing cfu/ml by the volume added to the plate. 
  2.4.2 Cefinase 
 The production of β-lactamase was determined by the Cefinase nitrocefin disk 
test (See Appendix E).  S. aureus isolates were subbed onto TSA plates containing 5% 
sheep blood and incubated in ambient air at 35-37°C for approximately 24 hr.  A 
positive and a negative control were included in each experiment.  The positive control 
was S. aureus ATCC 29213.  The negative control was Haemophilus influenzae ATCC 
10211.  Each cefinase disc was placed on a clean, flat surface and using a sterile Pasteur 
pipette, one drop of sterile distilled water was gently placed on each disc.  Isolated 
colonies were acquired from a fresh culture plate with a sterile wooden applicator stick 
and placed onto a Cefinase disc.  Appearance of a reddish color indicated the organism 




3.1 S.  aureus Results Against Fluoroquinolones 
A total of 122 MSSA and 22 MRSA clinical isolates were tested against 
gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin.  The distribution of MIC 
and MPC values for the MSSA strains are summarized in Table 3.1.  Table 3.2 shows 
the MIC and corresponding MPC values for the 22 MRSA strains against the same four 
fluoroquinolones.  The calculation of MIC50/90, MPC50/90, time above MPC 
measurements and other pharmacological related calculations are summarized in Table 
3.3. 
The MIC90 represents the drug concentration that inhibited growth of 90% of 
isolates tested by standardized susceptibility testing (Blondeau et al, 2003a).  Often, 
MIC data are considered based on the MIC90 values because the MIC90 is more 
convenient than analyzing each MIC value independently.  MIC90 data are also used 
globally as a marker for comparing in vitro antimicrobial potency.  The MPC90 is a 
concentration value that prevents growth of 90% of isolates tested by the MPC method 
against a particular antimicrobial agent.  Like the MIC90, this value is a more convenient 
way of interpreting MPC data as opposed to analyzing each value independently.  The 
MIC50 indicates the drug concentration that inhibited growth of 50% of isolates tested 
by the MIC.  The MPC50 is the drug concentration that inhibited growth of 50% of 
isolates tested by the MPC.  The MIC mode is the MIC value that occurred most 
frequently in a standard MIC susceptibility test involving many isolates. Similarly, the 
MPC mode is the MPC value that occurred most frequently in MPC testing of the same 
isolates.  
By broth microdilution testing of MSSA strains, MIC90 values for gemifloxacin 
and moxifloxacin were 0.063 µg/ml (mode=0.031 µg/ml), as compared to 0.25 µg/ml 
for gatifloxacin (mode=0.063 µg/ml) and 0.25 µg/ml for levofloxacin (mode=0.25 
µg/ml).  Four isolates had MICs >2 µg/ml for gatifloxacin as compared to two for 
gemifloxacin, two for levofloxacin and one for moxifloxacin.  By MPC (Table 3.1), the  
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Table 3.1:  The minimum inhibitory concentration (MIC) and mutant-prevention concentration (MPC) of four fluoroquinolones 
against 122 clinical isolates of methicillin-susceptible S. aureus. 
 
 
Fluoroquinolone <0.016 0.031 0.063 0.125 0.25 0.5 1 2 4 >8
Gatifloxacin 18 56 30 11 3 2 2
Gemifloxacin 37 47 29 5 1 1 2
Levofloxacin 10 44 59 4 3 2
Moxifloxacin 34 44 36 4 2 1 1
Gatifloxacin (n=119) 24 61 21 5 3 1 4
Gemifloxacin 27 66 16 4 4 1 4
Levofloxacin (n=121) 3 93 15 2 7 1
Moxifloxacin 2 89 20 3 5 1 2
No. of isolates with the following MIC (µg/ml) values
No. of isolates with the following MPC (µg/ml) values
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Table 3.2: Comparative minimum inhibitory concentration (MIC) and mutant-prevention concentration (MPC) (µg/ml) values of four 
fluoroquinolones against 22 methicillin-resistant strains of S. aureus. 
 
Organism #
MIC MPC MIC MPC MIC MPC MIC MPC
11 0.031 0.25 <0.008 0.063 0.125 0.5 0.016 0.125
12 4 16 2 16 8 64 1 8
13 4 16 2 16 8 64 1 8
14 4 16 2 32 8 64 2 8
15 0.25 0.25 <0.008 0.125 0.125 0.5 0.031 0.125
16 >8 32 4 32 16 64 2 8
17 0.063 0.25 <0.008 0.125 0.5 0.5 0.016 0.25
18 4 16 4 16 16 64 0.016 8
19 8 32 8 512 >16 128 0.016 16
36 4 16 2 32 8 64 2 8
37 0.063 0.25 <0.008 0.125 0.063 0.5 0.016 0.125
38 0.063 0.25 0.016 0.125 0.125 8 0.016 1
40 8 16 4 32 8 64 2 8
41 0.063 0.25 <0.008 0.125 0.125 0.5 0.125 0.25
42 8 32 >8 512 >16 128 4 16
43 8 16 2 16 8 64 2 8
44 0.063 0.25 <0.008 0.063 0.125 0.5 0.25 0.125
45 0.25 0.25 <0.008 0.063 0.25 0.5 0.031 0.031
46 8 0.25 >8 256 >16 128 8 16
47 8 32 4 32 8 64 4 8
49 4 16 2 16 8 64 2 8
50 4 16 4 16 0.16 64 2 8
Gatifloxacin Gemifloxacin Levofloxacin Moxifloxacin
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Time (h) >MIC50c 
Time (h) >MIC90c 
Time (h) >MPC50c 
Time (h) >MPC90c 
AUC0-24 (µg/ml)
Total Free Total Free Total Free Total Free Total Free Total Free Total Free Total Free
AUC0-24/MIC50c 814.3 651.4 12.8 10.2 270.9 108.4 4.2 1.7 192 142.1 6 4.4 1532.3 965.4 47.5 29.9
AUC0-24/MIC90c 205.2 164.2 6.4 5.1 133.3 53.3 1.1 0.4 192 142.1 3 2.2 753.9 474.9 11.9 7.5
AUC0-24/MPC50c 205.2 164.2 3.2 2.6 67.2 26.9 0.5 0.2 96 71 0.8 0.6 380 239.4 5.9 3.7
AUC0-24/MPC90c 51.3 41 1.6 1.3 16.8 6.7 0.03 0.01 48 35.5 0.4 0.3 190 119.7 2.9 1.8
Cmax/MIC50c 66.7 53.4 1.1 0.9 51.6 20.6 0.8 0.3 22.8 16.9 0.7 0.5 145.2 91.5 4.5 2.8
Cmax/MIC90c 16.8 13.4 0.5 0.4 25.4 10.2 0.2 0.08 22.8 16.9 0.4 0.3 71.4 44.9 1.1 0.69
Cmax/MPC50c 16.8 13.4 0.3 0.2 12.8 5.1 0.1 0.04 11.4 8.4 0.09 0.07 36 22.7 0.6 0.38
Cmax/MPC90c 4.2 3.4 0.1 0.08 3.2 1.3 0.006 0.002 5.7 4.2 0.04 0.03 18 11.3 0.3 0.19
aMIC50;MIC90 drug concentration (µg/ml) at which 50% and 90%, respectively, of isolates are inhibited.
bMPC50;MPC90 drug concentration (µg/ml)at which no mutants were recovered from 50% and 90% of isolates, respectively. 
cTime(h)>MIC(MPC)50/90-time serum drug concentrations remain above the MIC (MPC) for 50 and 90% of the isolates tested
cAUC0-24/MIC(MPC)50/90-area under the curve after 24 hours over the MIC (MPC) for 50 and 90% of the isolates tested
cCmax/MIC (MPC)50/90-maximum serum concentration over the MIC (MPC) for 50 and 90% of the isolates tested
120% protein binding (Nakashima et al , 1995). 326% protein binding (Fish and Chow, 1997).
260% protein binding (Allen et al , 2000). 437% protein binding (Stass and Proeve, 1999).
MSSA MRSA MSSA MRSAMSSA MRSA MSSA MRSA



























































































rank order of potency was moxifloxacin (mode 0.125 µg/ml; MPC90 0.25 µg/ml) > 
gemifloxacin (mode=0.125 µg/ml; MPC90 0.5 µg/ml) > gatifloxacin (mode=0.25 µg/ml; 
MPC90 1 µg/ml) = levofloxacin (mode 0.5 µg/ml; MPC90 1 µg/ml).  Eight isolates had 
MPCs >2 µg/ml against gatifloxacin as compared to five for gemifloxacin, ten for 
levofloxacin and three for moxifloxacin.   
The determination of the MIC90 or MPC90 values was additive starting from the 
lowest MIC or MPC value to the highest.  As such, a single or a few strains may change 
the MIC90 or MPC90 percent value by one doubling drug dilution.  Such was the case 
with this study.  For example, by MIC testing, gatifloxacin concentrations of 0.25 µg/ml 
inhibited 94% of the isolates tested, however, the drug concentration 0.125 µg/ml 
inhibited a large percentage of isolates as well (86%).  For the other three 
fluoroquinolones, concentrations one doubling dilution below the MIC90 inhibited 
<70% of isolates tested.   
By MPC testing, a drug concentration of 1 µg/ml inhibited 91% of isolates and 
0.5 µg/ml inhibited 87% of the isolates tested for gatifloxacin.  Similarly, the drug 
concentration of 0.5 µg/ml inhibited 93% of isolates tested with gemifloxacin and 0.25 
µg/ml inhibited 89% of the isolates tested.  For levofloxacin and moxifloxacin, 
concentrations one doubling dilution below the MPC90 inhibited 78% and 74% of 
isolates tested, respectively. 
The MIC and MPC values for the 22 MRSA strains are shown in Table 3.2.  As 
well, the calculations of MIC50/90, MPC50/90, and various pharmacological calculations 
with the MRSA strains are shown in Table 3.3.  Seven isolates had MICs to gatifloxacin 
≥8 µg/ml, seven at 4 µg/ml, and the remainder (eight isolates) at ≤0.25 µg/ml.  For 
gemifloxacin, three isolates had MICs ≥8 µg/ml, five at 4 µg/ml, six at 2 µg/ml, and the 
remainder (eight) at ≤0.016 µg/ml.  Thirteen isolates had MICs to levofloxacin ≥8 
µg/ml and the remainder (nine) at ≤0.5 µg/ml.  Only one isolate had an MIC to 
moxifloxacin at 8 µg/ml, two at 4 µg/ml, and the remainder were at 2 µg/ml (seven 
isolates) or less (12 isolates) – ten with MICs ≤0.25 µg/ml.   
The MPC values for MRSA strains were considerably higher than MIC values 
against all four agents: 13 isolates had MPCs ≥16 µg/ml for gatifloxacin; for 
gemifloxacin, 14 isolates had MPCs ≥16 µg/ml (3 at ≥256 µg/ml); for levofloxacin, 15 
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isolates had MPCs ≥8 µg/ml (14 at ≥64 µg/ml); for moxifloxacin, 14 isolates had MPCs 
≥8 µg/ml (three at 16 µg/ml).  Organisms with elevated MPCs to one agent had elevated 
MPCs to all four compounds. 
Previous published literature has argued that the time the drug concentration 
remains in excess of the MPC may be important for restricting the development of 
resistance (Blondeau et al, 2002b; Hansen et al, 2003).  Based on published data for the 
various fluoroquinolones showing maximum serum concentration and subsequent 
declining values over the duration of conventional dosing (Table 3.3), an estimation of 
the time (T) the serum drug concentration remains above the MIC90 and MPC90 for the 
various quinolones against MSSA strains resulted in a rank order of potency as follows:  
moxifloxacin T > MIC90 >24 hr and T > MPC90 >24 hr > levofloxacin (>24 hr and ~18 
hr respectively) > gatifloxacin (>24 hr and ~12 hr respectively) > gemifloxacin (~24 hr 
and ~9 hr respectively).   
It is argued that protein binding may affect drug concentrations required to 
eradicate an infection (Dalhoff and Schmitz, 2003).  The percentage of protein binding 
for each fluoroquinolone is indicated in Table 3.3.  An agent may show excellent in 
vitro data against an infecting organism, however, if the agent binds readily to proteins 
within the body the result may be less free (active) drug available for destroying the 
bacteria.  This may lead to higher concentrations necessary to eradicate an infection.  As 
such, pharmacokinetic parameters such as area under the concentration curve 
(AUC)/MIC and Cmax/MIC may be calculated with regards to the amount of free drug 
available.  These parameters are believed to be important in predicting the therapeutic 
outcome of patients with bacterial infections.  The impact of protein binding on drug 
concentrations necessary for eradication of bacterial infections, however, is still under 
investigation and there is no proof to date of protein binding significantly affecting the 
concentrations needed for bacterial eradication. 
3.2 MIC Results of S. aureus Isolates for Several Antimicrobial Agents 
Twenty-six of the 122 MSSA isolates were selected for further susceptibility 
studies with five non-quinolone agents.  The 22 MRSA were also further studied with 
the same non-quinolone agents.  Two additional MRSA isolates were collected and 
tested against the same antimicrobials.  MIC values for the 26 MSSA and 24 MRSA 
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were determined against nine antimicrobial agents.  For comparison reasons, the 
fluoroquinolone MIC data presented above will once again be described in this section.  
The distribution of MIC values for MSSA and MRSA are shown in Table 3.4.  Based 
on the MIC90, the most potent antimicrobial for MSSA was gemifloxacin (0.016 µg/ml) 
followed by moxifloxacin (0.063 µg/ml) > garenoxacin (0.25 µg/ml) = levofloxacin 
(0.25 µg/ml) = cloxacillin (0.25 µg/ml) > gatifloxacin (1 µg/ml) = vancomycin (1 
µg/ml) > cefazolin (2 µg/ml) > azithromycin (16 µg/ml).  The most potent antimicrobial 
for MRSA, based on MIC90 values, was vancomycin (1 µg/ml) followed by garenoxacin 
(2 µg/ml) > moxifloxacin (4 µg/ml) > gatifloxacin (8 µg/ml) = gemifloxacin (8 µg/ml) 
> cefazolin (16 µg/ml) > cloxacillin (32 µg/ml) = levofloxacin (32 µg/ml) > 
azithromycin (>512 µg/ml).  The in vitro potency based on MIC values is currently used 
for determining the dosing strategies for achieving and maintaining targeted drug 
concentrations for different antimicrobials against S. aureus.  
 3.3 MPC Results of S. aureus Isolates for Several Antimicrobial Agents 
 For the above isolates in which MIC values were determined, MPC values were 
also determined with the exception of 6 MSSA isolates against azithromycin, 17 MRSA 
against azithromycin, and 1 MSSA isolate against gatifloxacin.  MPC values were 
unavailable for these isolates for varying reasons.  For 20 isolates missing MPC data 
against azithromycin, the MPC experiment was not performed because the MIC values 
were extremely high (>512 µg/ml).  As MPC applies to organisms deemed to be 
susceptible to the antimicrobial agent by standardized susceptibility testing, MPC 
values would likely be inappropriate in such cases where the MIC value is above the 
NCCLS breakpoint (NCCLS, 2001a,b).  Such high concentrations would not be 
clinically achievable in the serum, therefore, MPC evaluations were not performed on 
these isolates.  The other four isolates missing MPC data were for reasons based on 
purity of the culture, obtaining the correct inoculum, or the availability of the agent.  
The fluoroquinolone MPC90 data presented in section 3.1 will once again be described 
as a comparison to the MPC90 data observed with the non-quinolone agents.  The 
number of isolates tested by both MIC and MPC was 50 for cefazolin, cloxacillin, 
garenoxacin, gemifloxacin, levofloxacin, moxifloxacin, and vancomycin.  For 
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Table 3.4: Distribution of minimum inhibitory concentration (MIC) values of S. aureus isolates (µg/ml). 
 
Antimicrobial Agent Susceptibility n1 <=0.004 <=0.008 0.008 0.016 0.031 <=0.063 0.063 0.125 0.25 0.5 1 2 4 8 16 32 64 >512
Azithromycin MSSA2 26 1 13 6 2 1 3
MRSA3 24 5 2 17
Total 50 0 0 0 0 0 0 0 0 0 1 18 8 0 2 1 0 0 20
Cefazolin MSSA 26 2 4 15 1 3 1
MRSA 24 3 3 1 8 9
Total 50 0 0 0 0 0 0 0 2 4 15 4 6 2 8 9 0 0 0
Cloxacillin MSSA 26 7 9 8 2
MRSA 24 4 10 1 2 4 2 1
Total 50 0 0 0 0 0 7 0 13 18 3 2 4 0 0 0 2 1 0
Garenoxacin MSSA 26 4 11 4 2 1 1 2 1
MRSA 24 6 3 1 2 12
Total 50 0 0 4 17 7 0 2 1 1 3 3 12 0 0 0 0 0 0
Gatifloxacin MSSA 26 9 5 4 4 1 3
MRSA 24 1 7 2 7 7
Total 50 0 0 0 0 10 0 12 4 6 0 1 3 7 7 0 0 0 0
Gemifloxacin MSSA 26 20 4 1 1
MRSA 24 8 2 6 5 1 2
Total 50 0 28 0 6 0 0 0 0 1 1 0 6 5 1 2 0 0 0
Levofloxacin MSSA 26 4 13 7 2
MRSA 24 1 7 1 1 8 3 2 1
Total 50 0 0 0 0 0 0 5 20 8 1 0 0 0 10 3 2 1 0
Moxifloxacin MSSA 26 2 3 9 7 3 2
MRSA 24 7 2 1 2 2 7 2 1
Total 50 2 0 3 16 9 0 3 1 2 0 4 7 2 1 0 0 0 0
Vancomycin MSSA 26 20 5 1
MRSA 24 19 4 1
Total 50 0 0 0 0 0 0 0 0 0 39 9 1 1 0 0 0 0 0  
 
1n=number of isolates tested  2MSSA=Methicillin-Susceptible S. aureus  3MRSA=Methicillin-Resistant S. aureus 
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azithromycin, 27 isolates were tested by both MIC and MPC and for gatifloxacin, 49 
isolates were tested by both MIC and MPC.  The results are shown in Table 3.5. 
 For MSSA infections, according to the MPC90 values, the most potent agent out 
of the nine agents tested was gemifloxacin (0.125 µg/ml).  After gemifloxacin, from 
most to least potent were moxifloxacin (0.5 µg/ml) > levofloxacin (1 µg/ml) > 
gatifloxacin (2 µg/ml) = garenoxacin (2 µg/ml) = cloxacillin (2 µg/ml) > vancomycin (4 
µg/ml) > azithromycin (32 µg/ml) > cefazolin (64 µg/ml).  For MRSA isolates, the most 
potent antimicrobial agents were vancomycin (8 µg/ml) and garenoxacin (8 µg/ml).  
After vancomycin and garenoxacin, from most to least potent for MRSA infections 
were moxifloxacin (16 µg/ml) > azithromycin (32 µg/ml) = gatifloxacin (32 µg/ml) > 
levofloxacin (128 µg/ml) > gemifloxacin (256 µg/ml) > cefazolin (512 µg/ml) > 
cloxacillin (>512 µg/ml).  For MRSA, such high MPC values to cloxacillin were 
expected, since cloxacillin is closely related to methicillin.  The MPC values may be 
important to address when determining new dosing strategies aimed at preventing 
resistance. 
 3.4 Comparison of the MIC and MPC Results 
The MIC and MPC data of S. aureus isolates against nine different 
antimicrobials are shown in Table 3.6.  For MSSA and MRSA strains tested against 
azithromycin (Table 3.6), the MIC90 was equal to 2 µg/ml and the MPC90 for these 
isolates was 32 µg/ml.  The MPC range was 8->512 µg/ml.  The MPC90 was 16-fold 
higher than the MIC90 for MSSA and MRSA against azithromycin.  No significant 
difference between MSSA and MRSA was observed for these organisms tested against 
azithromycin.  The MPC values appeared to be consistently 16-fold above the MIC 
values for both MSSA and MRSA strains.  
 For clinical isolates tested against cefazolin, MSSA and MRSA results differed 
greatly (Table 3.6).  For MSSA isolates, the MIC90 was 2 µg/ml.  The MPC mode was 1 
µg/ml while the MPC90 was 64 µg/ml.  For MRSA isolates, the MIC mode and the 
MIC90 were 16 µg/ml.  The MPC mode and MPC50 were 256 µg/ml.  The MPC90 was 
512 µg/ml.  For MSSA and MRSA, the MPC90 was 32-fold above the MIC90.  This 
shows that for both MSSA and MRSA isolates, the MPC values were consistently 
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Table 3.5: Distribution of mutant-prevention concentration (MPC) values of S. aureus isolates (µg/ml). 
 
Antimicrobial Agent Methicillin Susceptibility n1 0.031 0.063 0.125 0.25 0.5 1 >1 2 4 >4 8 16 32 64 128 256 512 >512
Azithromycin MSSA2 20 5 4 9 1 1
MRSA3 7 3 1 2 1
Total 27 0 0 0 0 0 0 0 0 0 0 8 5 11 0 0 0 1 2
Cefazolin MSSA 26 1 9 1 1 4 6 1 1 2
MRSA 24 5 16 3
Total 50 0 0 0 0 1 9 0 1 1 0 0 4 6 1 6 18 3 0
Cloxacillin MSSA 26 11 10 3 1 1
MRSA 24 1 1 22
Total 50 0 0 0 0 11 10 0 3 1 0 0 0 0 0 0 1 2 22
Garenoxacin MSSA 26 15 6 1 2 1 1
MRSA 24 6 2 1 1 13 1
Total 50 0 21 8 1 1 0 0 2 2 0 14 1 0 0 0 0 0 0
Gatifloxacin MSSA 25 22 1 1 1
MRSA 24 10 9 4 1
Total 49 0 0 0 32 0 0 0 1 1 0 1 9 4 1 0 0 0 0
Gemifloxacin MSSA 26 5 19 1 1
MRSA 24 3 7 6 5 1 2
Total 50 0 8 26 0 0 0 0 1 1 0 0 6 5 0 0 1 2 0
Levofloxacin MSSA 26 21 2 1 1 1
MRSA 24 7 1 1 1 11 3
Total 50 0 0 0 0 28 3 0 0 0 2 1 1 1 11 3 0 0 0
Moxifloxacin MSSA 26 17 5 1 1 2
MRSA 24 5 3 1 1 11 3
Total 50 0 0 22 8 1 2 1 0 2 0 11 3 0 0 0 0 0 0
Vancomycin MSSA 26 2 23 1
MRSA 24 11 11 2
50 0 0 0 0 0 0 0 2 34 0 11 3 0 0 0 0 0 0  
1n=number of isolates tested     2MSSA=Methicillin-Susceptible S. aureus     3MRSA=Methicillin-Resistant S. aureus 
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Table 3.6 Comparison of the minimum inhibitory concentration (MIC) and the mutant-prevention concentration (MPC) data for S. 
aureus isolates (µg/ml). 
 
Antimicrobial Agent Susceptibility n1 MIC mode MIC504 MIC904 MIC Range MPC mode MPC505 MPC905 MPC Range
Azithromycin MSSA2 20 1 1 2 0.5-8 32 32 32 8->512
MRSA3 7 1 1 2 1.0-2.0 8 16 32 8->512
Cefazolin MSSA 26 0.5 0.5 2 0.125-4 1 16 64 1-256
MRSA 24 16 8 16 1.0-16 256 256 512 128-512
Cloxacillin MSSA 26 0.125 0.125 0.25 <=0.063-0.5 0.5 1 2 0.5-512
MRSA 24 0.25 0.25 32 0.125-64 >512 >512 >512 256->512
Garenoxacin MSSA 26 0.016 0.016 0.25 0.008-1 0.063 0.063 2 0.063-8
MRSA 24 2 1 2 0.016-2 8 8 8 0.063-16
Gatifloxacin MSSA 25 0.031 0.063 1 0.031-2 0.25 0.25 2 0.25-8
MRSA 24 0.063, 4, 8 4 8 0.031-8 0.25 16 32 0.25-64
Gemifloxacin MSSA 26 <=0.008 <=0.008 0.016 <=0.008-0.5 0.125 0.125 0.125 0.063-4
MRSA 24 <=0.008 2 8 <=0.008-16 0.125 16 256 0.063-512
Levofloxacin MSSA 26 0.125 0.125 0.25 0.063-8 0.5 0.5 1 0.5-32
MRSA 24 8 8 32 0.063-64 64 64 128 0.5-128
Moxifloxacin MSSA 26 0.016 0.016 0.063 <=0.004-1 0.125 0.125 0.5 0.125-4
MRSA 24 0.016, 2 0.25 4 0.016-8 8 8 16 0.125-16
Vancomycin MSSA 26 0.5 0.5 1 0.5-4 4 4 4 2.0-16
MRSA 24 0.5 0.5 1 0.5-2 4 and 8 8 8 4.0-16  
 
1n=Number of isolates tested 
2MSSA=Methicillin-Susceptible S. aureus 
3MRSA=Methicillin-Resistant S. aureus 
4MIC50, MIC90=Drug concentrations at which 50% and 90% of the strains were inhibited, respectively 
5MPC50, MPC90=Drug concentrations at which resistant sub-populations for 50% and 90% of the strains were inhibited, respectively
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higher than the MIC values.  Furthermore, the MPC values observed for MRSA isolates 
were higher than those observed for MSSA isolates. 
 For MSSA isolates tested against cloxacillin (Table 3.6) the MIC90 was 0.25 
µg/ml and the MPC90 was 2 µg/ml.  For MRSA against cloxacillin, the MIC mode and 
MIC50 were 0.25 µg/ml, whereas, the MIC90 was 32 µg/ml.  According to the NCCLS, 
some MRSA isolates may show in vitro susceptibility to β-lactams (as seen by the MIC 
mode and MIC50) however, are not effective clinically and as such, are not 
recommended for treatment of MRSA (NCCLS, 2001a).  It is still interesting, however, 
to analyze the susceptibility behavior of MRSA with cloxacillin.  The MPC mode, 
MPC50, and MPC90 were >512 µg/ml.  For MSSA and MRSA respectively, the MPC90 
values were 8 and >16-fold above the respective MIC90 values.  Cloxacillin is closely 
related to methicillin, therefore, it is logical that the MRSA organisms would have a 
decreased susceptibility pattern compared to the MSSA isolates as observed with the 
MIC90 and MPC90 values. 
 Table 3.6 also shows that garenoxacin had an MIC mode and an MIC50 of 0.016 
µg/ml for MSSA while the MIC90 was 0.25 µg/ml.  The MPC mode and MPC50 were 
0.063 µg/ml, while the MPC90 was at 2 µg/ml.  For MRSA isolates, the MIC90 and MIC 
range were 2 and 0.016-2 µg/ml, respectively.  The MPC mode, MPC50, and MPC90 
were 8 µg/ml and the range recorded was 0.063-16 µg/ml.  For MSSA, the MPC90 was 
8-fold above the MIC90.  For MRSA, the MPC90 was 4-fold above the MIC90. 
MSSA isolates tested against gatifloxacin (Table 3.6) had a MIC90 of 1 µg/ml 
and a MPC90 of 2 µg/ml.  The MPC90 was 2-fold higher than the MIC90 for MSSA 
isolates tested against gatifloxacin.  For MRSA isolates tested against gatifloxacin, the 
MIC mode occurred at 3 different drug concentrations (0.063, 4, and 8 µg/ml).  Seven 
isolates had MIC values at each of the three concentrations.  The MIC90 was 8 µg/ml.  
The MPC mode and the MPC90 were 0.25 and 32 µg/ml, respectively.  The MPC90 was 
4-fold higher than the MIC90. 
 For isolates that were tested against gemifloxacin (Table 3.6), MSSA results 
were ≤0.008 µg/ml for both the MIC mode and the MIC50.  The MIC90 and MIC range 
were 0.016 and ≤0.008-0.5 µg/ml, respectively.  For MSSA isolates against 
gemifloxacin, 0.125 µg/ml was the drug concentration of the MPC mode, MPC50, and 
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MPC90.  The MPC90 was 8-fold higher than the MIC90 for MSSA isolates.  For MRSA 
isolates tested against gemifloxacin, the MIC mode was ≤0.008 µg/ml.  The MIC90 was 
8 µg/ml.  The MPC mode, MPC50, and MPC90 were 0.125, 16, and 256, respectively.  
For MRSA isolates, the MPC90 was 32-fold above the MIC90. 
 The MIC90 for MSSA isolates tested against levofloxacin (Table 3.6) was 0.25 
µg/ml.  The MPC90 was 1 µg/ml and the MPC range was 0.5-32 µg/ml.  For MRSA, the 
MIC mode and MIC50 were 8 µg/ml, whereas the MIC90 was 32 µg/ml.  The MPC90 and 
the MPC range were 128 and 0.5-128 µg/ml, respectively.  For both MSSA and MRSA, 
the MPC90 value was 4-fold above the MIC90 value. 
 For MSSA isolates tested against moxifloxacin (Table 3.6), the MIC90 value was 
0.063 µg/ml.  The MPC90 was 0.5 µg/ml.  For MRSA isolates against moxifloxacin, the 
MIC mode was 0.016 and 2 µg/ml with seven isolates existing at each of these two drug 
concentrations. The MIC90 was 4 µg/ml and the MPC90 was 16 µg/ml.  The MPC90 
value for MSSA was 8-fold greater than the MIC90 value.  The MPC90 value for MRSA 
was 4-fold greater than the MIC90. 
 Vancomycin data were similar for both MSSA and MRSA strains (Table 3.6).  
The MIC90 value for MSSA and MRSA was 1 µg/ml.  The MPC mode, MPC50, and 
MPC90 were all at 4 µg/ml for MSSA isolates.  The MPC90 for MRSA was 8 µg/ml.  
The MPC90 value for MSSA was 4-fold higher than the MIC90 value.  The MPC90 value 
for MRSA was 8-fold higher than the MIC90 value.   
 Individual colonies growing on plates containing elevated drug concentrations 
were collected (MPC-recovered isolates) and stored in 500 µl of skim milk at -70°C.  
MPC-recovered isolates have been described as recovered subpopulations with higher 
drug concentrations required for inhibition compared to the original heterogeneous 
population (parental population) from which the subpopulation was selected (Hansen et 
al, 2001).  The MPC-recovered isolates were re-tested by MIC methodologies (Table 
3.7).  Except for vancomycin, all MPC-recovered isolates with high MPC values had 
elevated MIC levels compared to their original parental MIC values.   
 3.5 Overcrowding Results 
 The issue concerning overcrowding was evaluated using S. aureus isolate #4 and 
the drug levofloxacin.  Overcrowding is the growth of an organism due to the lack of 
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Table 3.7: Minimum inhibitory concentrations (MICs) of recovered S. aureus isolates 
from mutant-prevention concentration (MPC) drug plates. 
 
Antimicrobial Agent Organism # Original MIC Recovered MIC Ratio 
Azithromycin 4 1 >128 >128 
  9 1 32 32 
  21 1 >128 >128 
  25 1 32 32 
  34 1 64 64 
  35 1 >128 >128 
  41 1 >128 >128 
Cefazolin 14 1 64 64 
  35 0.25 64 256 
  47 1 64 64 
Cloxacillin 11 0.125 >64 >512 
  13 0.125 >64 >512 
  16 0.125 32 256 
  35 <=0.064 32 >512 
  36 0.25 32 128 
  37 2 32 16 
  40 0.125 >64 >512 
  43 0.125 >64 >512 
  48 0.125 >64 >512 
Garenoxacin 14 2 16 8 
Gatifloxacin 5 0.031 0.25 8 
  10 0.031 0.25 8 
  11 0.031 0.25 8 
  24 0.031 0.25 8 
  26 0.031 2 64 
  27 0.031 0.25 8 
  29 0.031 0.5 16 
  33 0.031 0.25 8 
  34 0.031 0.125 4 
  35 0.031 0.125 4 
Gemifloxacin 5 <=0.008 0.125 >16 
  6 <=0.008 0.125 >16 
  7 <=0.008 0.125 >16 
  8 <=0.008 0.063 >8 
  9 <=0.008 0.125 >16 
  10 <=0.008 0.063 >8 
  15 <=0.008 0.125 >16 
  17 <=0.008 0.125 >16 
  23 <=0.008 0.125 >16 
  25 <=0.008 0.125 >16 
  29 <=0.008 0.125 >16 
  30 <=0.008 0.125 >16 
  31 <=0.008 0.125 >16 
  32 <=0.008 0.125 >16 
  33 <=0.008 >1 >128 
  41 <=0.008 1 128 
Levofloxacin 21 0.063 0.5 8 
  34 0.125 8 64 
  35 0.063 16 256 
  38 0.125 8 64 
  39 0.125 8 64 
  48 0.125 8 64 
Moxifloxacin 17 0.016 0.25 16 
  20 <=0.004 0.125 >32 
  22 0.008 0.125 16 
  23 0.008 0.125 16 
  24 <=0.004 0.125 >32 
  32 0.008 0.25 32 
  33 0.016 2 128 
  34 0.031 2 64 
  35 0.016 2 128 
  38 0.016 2 128 
  39 0.016 4 128 
Vancomycin 26 0.5 0.25 0.5 
  41 0.5 0.5 1 
  46 1 0.5 0.5 
  48 0.5 0.5 1 
  49 0.5 0.5 1 
  50 0.5 0.5 1 
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contact of that organism to the antimicrobial agent.  This was a concern for the MPC 
concept, since this test is based on a large inoculum of bacteria (≥109 cfu/ml) and with 
this large inoculum, there may be a possibility that the antimicrobial agent was not in 
contact with the organism due to excess organism interfering with other organism/drug 
contact.  In this case, growth observed at high drug concentrations are due to the 
overcrowding phenomenon. 
 The results of the overcrowding experiment are displayed in Table 3.8.  There 
was no significant change in MPC values when plating out various volumes of 
inoculum.  One doubling dilution change occurred between plating 300 and 400 µl of 
inoculum.  This was insignificant, since the volume plated for S. aureus organisms was 
100 µl.  The MPC results appeared consistent despite the various volumes of inoculum 
added to the plates.   
 3.6 Characterization of MPC-recovered Populations 
  3.6.1 Vancomycin MPC-recovered Populations 
 Some S. aureus isolates had elevated MPC values to vancomycin compared to 
the MIC values.  When the MPC-recovered populations were re-tested for their MIC, 
elevations in the MIC value were not observed.  Further characterization of the 
vancomycin MPC-recovered samples was performed to help determine the mechanism 
of resistance. 
 PCR was performed on the MPC-recovered populations that displayed high 
MPC values to vancomycin.  Genes that confer glycopeptide resistance in enterococci 
include vanA, vanB, vanC, vanC2/C3, vanD, vanE, and vanG (McKessar et al, 2000).  
An attempt to detect these genes in the isolates with high MPC values proved 
unsuccessful (Figures 3.1-3.3).  With the possibility of the isolates reverting back to 
susceptible phenotypes, samples were taken directly from their storage media and were 
prepared for PCR, as opposed to growing them overnight in the absence of vancomycin.  
Positive controls for vanC2/C3, vanD, vanE, and vanG were unavailable at the time of 
experimentation, however, recent studies using the primers listed in Table 2.1 proved 
that the primers were functioning as expected (data not shown).  All tested samples 
were negative for all above vancomycin-resistant genes.  Figure 3.1 shows organisms 
tested for the presence of vanA, vanB, and vanC.  A faint band that looked to be the size  
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Table 3.8: Influence of inoculum volume on the mutant-prevention concentration 
(MPC) for levofloxacin. 
 
Volume added to the plates (µls) cfu1 added to each plate MPC (µg/ml)
25 1.3 x 108 0.5
50 2.6 x 108 0.5
100 5.1 x 108 0.5
150 7.7 x 108 0.5
200 1.0 x 109 0.5
250 1.3 x 109 0.5
300 1.5 x 109 0.5
400 2.1 x 109 1
600 3.1 x 109 1
800 4.1 x 109 1
1000 5.1 x 109 1
1250 6.4 x 109 1
1500 7.7 x 109 1
1750 9.0 x 109 1
2000 1.0 x 1010 1  
 











Figure 3.1: Polymerase chain reaction (PCR) for vanA, vanB, and vanC genes in S.  





















Lane 1= 123 bp Marker 
Lane 2= vanC-Positive Control 
Lane 3= Negative Control 
Lane 4=41-MPC-recovered  
Lane 5=46-MPC-recovered  
 (isolated from a plate  
containing 2 µg/ml  
vancomycin) 
Lane 6=46-MPC-recovered  
 (isolated from a plate  






   1      2     3     4     5     6       1      2     3      4     5     6     igure 3.2: Polymerase chain reaction (PCR) for vanC2/C3 and vanD genes in S.  
ureus isolates with elevated MPC values (MPC-recovered). 
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Lane 1=123 bp Marker 
Lane 2=Negative Control 
Lane 3=41-MPC-recovered 
Lane 4=46-MPC-recovered  
 (isolated from a plate  
 containing 2 µg/ml  
 vancomycin) 
Lane 5=46-MPC-recovered  
 (isolated from a plate  
 containing 4 µg/ml  
 vancomcycin) 
Lane 6=29213-MPC-recovered 
6   1      2     3     4     5     
 
Figure 3.3: Polymerase chain reaction (PCR) for vanE and vanG genes in S.  aureus 
isolates with elevated MPC values (MPC-recovered). 
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of vanB was observed, however, this band appeared in both the MPC-recovered and the 
parental isolates, therefore, it was not the cause of the increased MPC value observed in 
the MPC-recovered population.  Figure 3.2 displays the gel for the vanC2/C3 and vanD 
genes.  Figure 3.3 shows non-specific binding occurring at approximately 200 and 400 
bp.  These bands do not correspond to the expected sizes of vanE (513 bp) and vanG 
(810 bp) and were, therefore, disregarded. 
 A MPC-recovered population that had an elevated MPC value for vancomycin 
(8 µg/ml) was further studied using Electron Microscopy.  The cells were grown on 
media containing drug to prohibit the population from reverting back to a wild type 
susceptible phenotype.  Cells were then fixed with glutaraldehyde and given to Karen 
Slattery (Electron Microscopy Technician, Department of Pathology, SHR) for slicing, 
staining, and analysis.  Blind measurements of the cell walls of populations #41 and 
#41m were recorded.  An electron micrograph of the susceptible parent population 
(#41) at 100,000X is shown in Figure 3.4.  Figure 3.5 is the electron micrograph of the 
intermediate-resistant MPC-recovered population (#41m) at 100,000X.   
 Statistical analysis was performed on the cell wall measurements to determine if 
the difference observed in cell wall thickness was significant.  The mean thickness of 
the cell wall from the susceptible parental population (µ#41) was 327±37 Å.  The mean 
thickness of the cell wall from the MPC-recovered population (µ#41m) was 466±113 Å.  
At the 1% significance level (α=0.01), the critical value (Zc) was approximately 2.33 
(Mann, 1998a).  The test value (Zt) was calculated to be 6.6.  The test value (Zt=6.6) 
exceeded the critical value (Zc=2.33), therefore, the null hypothesis (Ho) which stated 
that the cell wall populations were equal at 327 Å was rejected.  The mean thickness of 
the cell wall of population #41m (466 Å) was too far from the hypothesized population 
of µ#41=327 Å to be due to chance or sampling error alone.  The cell wall of population 
#41m was, indeed, significantly thicker than the cell wall of population #41. 
3.6.2 Azithromycin MPC-recovered Populations 
 Isolates with high MPC values to the azalide, azithromycin, were tested for the 
presence of macrolide-resistant genes (ermA, ermB, ermC, mefA/E, and msrA/B) by 
PCR.  The MPC-recovered populations of isolates 4 (Az4), 34 (Az34), and 35 (Az35) 









































Figure 3.6: Polymerase chain reaction (PCR) for ermC in MPC-recovered populations 
from azithromycin drug plates. 
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Az29) were ermC-negative.  No positive control was available, however, the presence 
of the ermC gene was confirmed through sequencing and NCBI (National Centre for 
Biotechnology Information) searches.  The NCBI BLAST search revealed that the 
sample sequence had a 98% homology to the ermC gene in S. aureus M798 
(gi│18542235).  Four base pairs out of 346 base pairs did not match up.  This may be 
because the strain used in this study was a clinical S. aureus strain and was likely 
different from the strain in the database.  Also, the search indicated that there was a 0% 
chance that the homology between the query and the S. aureus ermC gene was due to 
randomness (E-value=0).   The parents of these MPC-recovered populations (4, 34, and 
35) were all negative for the ermC gene (Figure 3.7). 
 S. pneumoniae MIC and MPC data were collected (Table 3.9).  I further 
characterized the isolates with elevated MPC values by PCR.  Like the S. aureus MPC-
recovered populations that were ermC-positive, some MPC-recovered populations of S. 
pneumoniae had macrolide-resistant genes as well (Table 3.9).  Figure 3.8 shows an 
example of both mefA- and ermB-positive MPC-recovered populations.  The parents of 
these MPC-recovered populations were negative for the macrolide-resistant genes.  An 
example gel is shown in Figure 3.9.  Isolates A2, A6, A7, and A12 had acquired the 
macrolide efflux gene, mefA.  Isolates A5 and A15 had acquired the erythromycin 
resistance methylase gene, ermB (Blondeau et al, 2004). 
3.7 Application of the MIC and MPC Results 
 3.7.1 Pharmacokinetic Curves 
According to Zhao and Drlica (2001), the mutant-selection window (MSW) is 
an important clinical parameter that exists between the MIC and the MPC values.  At an 
inoculum of ≥109 cfu/ml, the MSW signifies the concentrations of drug that optimally 
select resistant phenotypes.  Serum concentrations within the MSW select resistant 
subpopulations as discussed in section 1.4.4.1.  It is desirable to minimize the time 
period that the serum drug concentration is within the MSW to prevent resistant 
subpopulations from proliferating.  An optimal drug to use would be one with a narrow 
MSW thereby decreasing the risk of emerging resistant mutants.  Another possibility for 
preventing resistance is by treating at or above the MPC value thereby moving drug 
concentrations away from the MSW.  Hence, the MSW may be a significant factor to 
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 M=123 bp Marker 
29213=Negative Control 
4=Parental Isolate #4 
34=Parental Isolate #34 
35=Parental Isolate #35 
Figure 3.7: Polymerase chain reaction (PCR) for ermC in parental isolates of MPC-
recovered populations of S. aureus that were positive for ermC. 
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Table 3.9: S. pneumoniae isolates with elevated mutant-prevention concentration (MPC) (µg/ml) levels and the presence or absence 
of macrolide-resistance determinants. 
 
Isolate # Selecting Agent Penicillin MIC1 Penicillin Susceptibility MIC1 MPC MICrec2 mefA
3 ermB 4
A1 Erythromycin <=0.008 Sensitive 0.063 0.5 4 - -
A2 Erythromycin <=0.008 Sensitive 0.063 >=4 8 + -
A3 Erythromycin 0.016 Sensitive 0.031 2 16 - -
A4 Erythromycin 0.125 Intermediate 0.125 >=4 >16 - -
A5 Erythromycin 0.016 Sensitive 0.031 >=4 >16 - +
A6 Erythromycin <=0.008 Sensitive 0.063 2 8 + -
A7 Clarithromycin <=0.008 Sensitive 0.063 1 4 + -
A8 Clarithromycin 0.016 Sensitive 0.031 1 4 - -
A9 Clarithromycin <=0.008 Sensitive 0.031 1 1 - -
A10 Azithromycin 0.016 Sensitive 0.25 >=8 >32 - -
A11 Azithromycin <=0.008 Sensitive 0.125 >=8 16 - -
A12 Azithromycin <=0.008 Sensitive 0.125 >=8 8 + -
A13 Azithromycin 0.016 Sensitive 0.125 >=8 >32 - -
A14 Azithromycin <=0.008 Sensitive 0.063 2 8 - -
A15 Azithromycin 0.016 Sensitive 0.063 >=8 >32 - +
A16 Azithromycin <=0.008 Sensitive 0.125 8 >32 - -  
 
1MIC=Minimum Inhibitory Concentration (µg/ml) 
2MICrec=Minimum Inhibitory Concentration (µg/ml) of isolates recovered from MPC plates 
3mefA=Macrolide Efflux Gene 





Figure 3.8: Polymerase chain reaction (PCR) for mefA and ermB in S. pneumoniae 
MPC-recovered populations from MPC plates containing erythromycin. 
Lane 1=mefA-Positive  
Control 
Lane 2=ermB-Positive  
 Control 
Lane 3=Negative Control 
Lane 4=MPC-recovered A1 
Lane 5=MPC-recovered A2 
Lane 6=MPC-recovered A3 
Lane 7=MPC-recovered A4 
Lane 8=MPC-recovered A5 










Lane 1=mefA-Positive  
Control 
Lane 2=ermB-Positive  
 Control 
Lane 3=Negative Control 
Lane 4=MPC-recovered A16 
Lane 5=Parental Isolate A2 
Lane 6=Parental Isolate A5 
Lane 7=Parental Isolate A6 
Lane 8=Parental Isolate A7   




Figure 3.9: Polymerase chain reaction (PCR) for mefA and ermB in S. pneumoniae 
parental isolates of the MPC-recovered populations showing the presence of either mefA 
or ermB genes. 
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consider when developing new dosing strategies for novel antimicrobials.  All of the 
pharmacokinetic curves shown in this thesis were collected from various sources as 
indicated in each figure.  The MIC90, MPC50, and MPC90 values presented in this thesis 
were superimposed on each curve.  Determination of the MSW was then possible for 
each antimicrobial agent. 
3.7.1.1 Quinolones 
    3.7.1.1.1 Garenoxacin 
The MSW of MSSA to garenoxacin was 0.25-2 µg/ml based on a single 600 mg 
oral dose (Figure 3.10).  At this dose, drug concentrations would remain above the 
MSW for the entire dosing period.  Since the MPC90 (2 µg/ml) was below the maximum 
serum concentration (~10 µg/ml), this level is achievable in patients, thereby preventing 
the selection of resistant subpopulations in a large heterogeneous population of cells.  
 The MSW of garenoxacin for MRSA isolates involved most of the 
pharmacokinetic curve at concentrations between 2 and 8 µg/ml (Figure 3.11).  At the 
dosage recommended by the manufacturer, serum concentrations would lie within the 
MSW for ~17 hr.  Time above the MPC90 was 4.5-5.5 hr.  Because the MPC90 value 
existed below the maximum serum concentration, treatment at the MPC value may be 
achievable with minimal side effects.  
    3.7.1.1.2 Gatifloxacin 
  Gatifloxacin tested against MSSA showed that for the recommended dosage of 
400 mg once a day, serum drug concentrations were within the MSW for ~6 hr (Figure 
3.12).  The MSW was 1-2 µg/ml.  Time above the MPC90 was ~6 hr.  Treating above 
the MPC level may be achievable, since the MPC was 2 µg/ml and the maximum serum 
concentration was above 4 µg/ml.  
The gatifloxacin curve against MRSA portrayed a MSW (8-32 µg/ml) that 
existed above the maximum serum concentration (Figure 3.13).  The MPC value is not 
achievable in the serum for this reason.  According to the data presented, gatifloxacin 
serum concentrations do not exceed the MIC value, therefore, susceptible cells may 































Figure 3.10: Relationship of serum concentration of garenoxacin to the mutant-































Figure 3.11: Relationship of serum concentration of garenoxacin to the mutant- 
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Figure 3.12: Relationship of serum concentration of gatifloxacin to the mutant-












1 6 12 24
MIC90 = 8






















Figure 3.13: Relationship of serum concentration of gatifloxacin to the mutant-
prevention concentration (µg/ml) for methicillin-resistant S. aureus. 
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   3.7.1.1.3 Gemifloxacin 
 The MSW of gemifloxacin to MSSA strains appeared to be quite narrow and 
low on the pharmacokinetic curve (0.016-0.125 µg/ml) (Figure 3.14).  There was, 
however, a small time frame of ~1.5 hr in which the concentration of drug was within 
the MSW at the dosage recommended by the manufacturers (320 mg once-daily).  Re-
administration of this agent before serum levels reach the MSW would move the serum 
concentrations away from the MSW.  Because the MPC90 (0.125 µg/ml) was lower than 
the maximum serum concentration (1.5 µg/ml), MPC90 levels are achievable and 
sustainable within the serum of an infected patient.  Based on the recommended dosage, 
time above the MPC90 was ~16 hr.   
For MRSA, the MSW was above the maximum serum concentration based on 
the MPC concept/model (the MSW was 8-256 µg/ml and the maximum serum 
concentration was ~1.5 µg/ml) (Figure 3.15).  A similar observation was made with 
gatifloxacin and MRSA organisms.  Treatment failure would likely be due to the 
outgrowth of susceptible cells, since the serum concentration does not reach even the 
MIC level (Tillotson et al, 2001). 
    3.7.1.1.4 Levofloxacin 
  The MSW for levofloxacin was low and narrow for MSSA organisms (0.25-1 
µg/ml).  At the end of the dosing period, however, there was ~6 hr in which the serum 
drug concentration existed within the MSW (Figure 3.16).  Like gemifloxacin and 
MSSA, this may be avoided by re-administration of the drug before the serum 
concentration reaches the MSW (i.e., changing the dosage regimen).  If this is practical, 
serum concentrations would cease to exist within the MSW, making this agent effective 
at resolving an infection and preventing the outgrowth of resistant subpopulations with 
minimal adverse reactions.  For levofloxacin and MSSA, the serum drug concentrations 
remain above the MPC90 for ~18 hr.   
For MRSA isolates, the MSW existed above the maximum serum concentration 
(Figure 3.17).  The maximum serum concentration was ~6 µg/ml and the MSW was 32-
128 µg/ml.  This was similar to the findings of gemifloxacin and gatifloxacin and 
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Figure 3.14: Relationship of serum concentration of gemifloxacin to the mutant-
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Figure 3.15: Relationship of serum concentration of gemifloxacin to the mutant- 
prevention concentration (µg/ml) for methicillin-resistant S. aureus. 
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Figure 3.16: Relationship of serum concentration of levofloxacin to the mutant- 
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Figure 3.17: Relationship of serum concentration of levofloxacin to the mutant- 




   3.7.1.1.5 Moxifloxacin 
 For moxifloxacin and MSSA, the MSW was below the pharmacokinetic curve 
and was very narrow (0.063-0.5 µg/ml) (Figure 3.18).  The amount of time that the 
serum drug concentrations were within the MSW was zero (based on approved dosing), 
thereby decreasing the chance that a resistant phenotype to moxifloxacin may be 
selected out.  Resistant phenotypes that may be present in large heterogeneous 
populations of cells would likely be destroyed along with the susceptible phenotypes by 
treatment with moxifloxacin at a 400 mg once-daily dosing.   
For MRSA infections, the MSW was extremely high on the pharmacokinetic 
curve (4-16 µg/ml) and it involved the upper portion of the pharmacokinetic curve 
(Figure 3.19).  Treatment failure may be the result of outgrowth of susceptible cells, 
since the serum drug concentration exceeded the MIC value for only a short period of 
time (~3 hr during the dosing period) (Tillotson et al, 2001).  The MPC90 value is likely 
unachievable, since the maximum serum concentration (~4.5 µg/ml) is below the 
MPC90 value (16 µg/ml). 
   3.7.1.2 Glycopeptide 
    3.7.1.2.1 Vancomycin 
The MSW for vancomycin against MSSA (Figure 3.20) included only a small 
portion of the pharmacokinetic curve after a dosage of 500 mg (Healy et al, 1987).  The 
MSW for MSSA was 1-4 µg/ml.  Re-administration of this agent before serum 
concentrations reach the MSW would move the serum levels away from the MSW.   
The MSW for MRSA against vancomycin was 1-8 µg/ml (Figure 3.21).  For 
MRSA systemic infections, the pharmacokinetic curve existed within the MSW for ~7 
hr.  Within this time, resistant subpopulations may be selected out of large 
heterogeneous populations.  The MPC90 levels may possibly be achievable in a patient, 
since these levels were below the maximum serum concentration which was ~40 µg/ml.  
Time spent above the MPC90 value was ~7 hr. 
Despite the overall observations showing the success of vancomycin activity, a 
small number of organisms resulted in MPC values that exceeded the NCCLS 
breakpoint for susceptible isolates (NCCLS, 2001a).  These isolates were further 





























Wise et al, 1999
Blondeau et al, 2000b
MIC90 = 0.063





Figure 3.18: Relationship of serum concentration of moxifloxacin to the mutant-
prevention concentration (µg/ml) for methicillin-susceptible S. aureus. 
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Figure 3.19: Relationship of serum concentration of moxifloxacin to the mutant- 
prevention concentration (µg/ml) for methicillin-resistant S. aureus. 
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Figure 3.20: Relationship of serum concentration of vancomycin to the mutant- 
prevention concentration (µg/ml) for methicillin-susceptible S. aureus. 

































Figure 3.21: Relationship of serum concentration of vancomycin to the mutant- 




  3.7.1.3 β-lactams 
    3.7.1.3.1 Cloxacillin 
  For cloxacillin against MSSA, the MSW was 0.25-2 µg/ml and involved only a 
small portion of the pharmacokinetic curve at an i.v. dose of 500 mg over 10 min 
(Figure 3.22) (Soldin et al, 1980).  This observation supports previous literature 
indicating that cloxacillin is an appropriate agent for effectively eradicating a systemic 
MSSA infection (Turnidge and Grayson, 1993; de Gorgolas et al, 1995; Ribera et al, 
1996; Somekh et al, 1999). 
For MRSA infections, the MSW involved much of the pharmacokinetic curve 
and extended beyond the maximum serum concentration (Figure 3.23).  The MSW was 
32->512 µg/ml while the maximum serum concentration exists at ~100 µg/ml.  To 
succeed in eradication of a large MRSA population with cloxacillin, one must treat at 
the MPC level which is beyond the maximum serum concentration and as such, 
unachievable.  This confirms the well-known fact that cloxacillin is inappropriate for 
the treatment of MRSA since methicillin-resistance also confers resistance to cloxacillin 
(Franciolli et al, 1991). 
    3.7.1.3.2 Cefazolin 
 The MSW for cefazolin against MSSA and MRSA involved most of the 
pharmacokinetic curve at a dosage of 500 mg iv injection (Figure 3.24 and Figure 3.25) 
(Kirby and Regamey, 1973).  For MSSA infections, the MSW was 2-64 µg/ml and for 
MRSA infections, the MSW was 16-512 µg/ml.  At the current recommended approved 
dosing, serum drug concentrations exist within the MSW for MSSA, increasing the risk 
of this agent selecting for resistant subpopulations, if present.  Since MRSA are already 
resistant to cefazolin, this agent would be inappropriate for the treatment of MRSA 
infections, however, it is still interesting to study the MPCs in relation to the 
pharmacokinetics.  Serum concentrations remain in the MSW for ~4 hr.  It is possible 
that different levels of resistance are present within a population and that with high 
inocula and antimicrobial selective pressure, these higher level resistant cells may be 
selected from the population.  The relationship of this, however, to what occurs 
clinically is unknown.  For MSSA, the MPC90 value (64 µg/ml) may be achievable 






























Figure 3.22: Relationship of serum concentration of cloxacillin to the mutant-
prevention concentration (µg/ml) for methicillin-susceptible S. aureus. 






























Figure 3.23: Relationship of serum concentration of cloxacillin to the mutant-





























Figure 3.24:  Relationship of serum concentration of cefazolin to the mutant-prevention 



























Figure 3.25:  Relationship of serum concentration of cefazolin to the mutant-prevention 




(512 µg/ml) is not likely achievable, since this value is beyond the maximum serum 
concentration (~120 µg/ml).  According to the presented in vitro data, cefazolin may 
potentially select for resistant subpopulations in MSSA infections and higher levels of 
resistance in MRSA infections. 
3.7.1.4 Macrolide 
    3.7.1.4.1 Azithromycin 
For azithromycin, both MSSA and MRSA portrayed a MSW that extended 
above the maximum serum concentration (Figures 3.26 and 3.27).  The MSW for both 
MSSA and MRSA was 2-32 µg/ml.  Because the MPC90 value (32 µg/ml) lies above the 
maximum serum concentration (0.5 µg/ml), it is unlikely that this concentration would 
be safely achieved in the blood.  Treatment failure with azithromycin may be due to the 
proliferation of susceptible cells, since the serum drug concentration lies below the 
MIC90 value for the majority of the dosing period (Tillotson et al, 2001).  
 3.8 Retrospective Multiple Sequential S. aureus Study 
 An initially susceptible population may develop into a resistant population as a 
result of in vivo selective pressure of an antimicrobial agent.  As discussed earlier 
(section 1.4.1), resistant organisms can emerge from spontaneous mutations.  In many 
cases, the number of bacterial organisms exceeds the spontaneous mutation frequency 
(Gould and MacKenzie, 2002), giving rise to resistant organisms that may selectively be 
enriched by an antimicrobial agent.  This process has been shown to exist in the 
laboratory setting (Firsov et al, 2003).  Few studies have been performed on the 
susceptibility behavior of multiple organisms isolated from patients who have failed 
antimicrobial therapy.  This information may help provide evidence of a bacterial 
population changing its susceptibility patterns within a patient while the patient 
undergoes antimicrobial therapy. 
Twenty-eight multiple sequential isolates were collected from nine different 
patients.  Isolates were collected from November (2001) to February (2002) for patients 
#1 and #6.  Patient #2 had isolates that were collected between October (2001) and 
January (2002).  Isolates from patients #3 and #4 were collected between the months of 
December (2001) and January (2002).  For patients #5 and #8 isolates were collected in 


































Figure 3.26: Relationship of serum concentration of azithromycin to the mutant-
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Figure 3.27: Relationship of serum concentration of azithromycin to the mutant-
prevention concentration (µg/ml) for methicillin-resistant S. aureus. 
 79
patient #7 were collected between February (2002) and March (2002) and isolates from 
patient #9 were collected between December (2001) and February (2002).  MIC and 
MPC values were determined for each isolate against the antimicrobials prescribed to 
the patients as well as other agents of interest. 
 PFGE was performed on each isolate to ensure the sequential infecting isolates 
were from the same origin (same strain of S. aureus).  Figures 3.28 and 3.29 display the 
PFGE results.  Patients one, two, three, five, six, seven, eight, and nine showed similar 
band patterns amongst the sequential isolates, suggesting that the infecting organisms 
were, indeed, the same strain of S. aureus throughout the duration of infection and 
treatment.  In patient four, isolates #12 and #16 had unique band patterns when 
compared to the other organisms isolated from this patient, suggesting that these two 
strains of S. aureus were different than the other strains (isolates #13-15).  Patient four 
was likely infected with more than one strain of S. aureus.  The other patients, however, 
appeared to be infected with the same strain of S. aureus throughout the duration of 
their infection.  With the knowledge of the same infecting strain, any differences 
observed in MPC values may be due to this population of cells developing resistance 
through selective therapy. 
Information regarding patient antimicrobial therapy and the ability of isolates to 
produce β-lactamase was assessed.  The agents prescribed to each patient are shown in 
Table 3.10. The isolates were tested for their ability to produce the enzyme, β-lactamase 
using the Cefinase test.  The data are shown in Table 3.11.  In patient four, isolate #12 
was negative for β-lactamase production while isolates #13-16 were positive.  This may 
be explained by the PFGE results which indicated that isolate #12 was a different strain 
compared to the other isolates collected from this patient.   
Table 3.12 displays the MPC data of the retrospective sequential isolates.  For 
clindamycin and rifampin, there appeared to be no MPC endpoint and even if so, it 
would likely be beyond clinically achievable drug concentrations.  This phenomenon 
was discussed previously with rifampin (Allen, 2003).  Seven small increases in MPC 
among sequential isolates were observed against the drugs prescribed to the patients.  
The last two S. aureus organisms isolated in patient one have 2-fold higher MPC values 
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Figure 3.28 Pulsed field gel electrophoresis (PFGE) on sequential multiple isolates of 













9 10 11 12 13 14 15 16 17
Patient 4
Patient 5







Lane 9 = Repeat of isolate #9 from patient 2 (refer to figure 3.28) 
 
Figure 3.29: Pulsed field gel electrophoresis (PFGE) on sequential multiple isolates of 




Table 3.10: Antimicrobial history of patients from whom sequential S. aureus isolates were recovered. 
 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9
Pip/Tazoa Rifampin Gentamicin Cloxacillin Cefuroxime Pip/Tazoa Not Available Cefazolin Cephalexin
Clindamycin Cefotaxime Vancomycin Gentamicin Ciprofloxacin
Ciprofloxacin Clindamycin Cefazolin Cloxacillin
Cefazolin Cloxacillin
Cefotaxime Gentamicin  
aPip/Tazo=Piperacillin/Tazobactam
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Table 3.12: Mutant-prevention concentration (MPC) data on the sequential S. aureus isolates (µg/ml). 
 
Isolate Cefazolin Cefotaxime Cefuroxime Cephalexin Cipro.1 Clind.2 Cloxacillin Gentamicin Rifampin Pip/Tazo3 Vanco.4
Patient 1 1 1 2 2 16 16 >2 0.5 >512 >16 1 4
2 1 4 2 16 16 >2 0.5 >512 >16 2 4
3 1 4 2 32 16 >2 0.5 32 >16 1 4
Patient 2 4 1 4 2 16 4 >2 1 >512 >16 1 4
5 1 8 2 16 2 >2 0.5 >512 >16 1 4
6 1 4 2 16 2 >2 0.5 >512 >16 1 4
7 0.5 4 2 16 2 >2 0.5 >512 >16 2 4
8 0.5 4 2 16 2 >2 0.5 >512 >16 2 4
9 0.5 4 2 16 2 >2 0.5 >512 >16 1 4
Patient 3 10 128 4 4 128 2 >2 1 8 >16 32 4
11 128 4 4 128 2 >2 2 8 >16 32 4
Patient 4 12 4 8 4 128 2 >2 1 16 >16 32 4
13 1 2 2 16 4 >2 0.25 64 >16 2 4
14 1 2 1 16 4 >2 0.5 64 >16 4 4
15 1 2 1 16 4 >2 0.5 64 >16 2 8
16 128 >32 >32 128 64 >2 >4 16 >16 128 4
Patient 5 17 4 2 2 64 1 >2 1 8 >16 16 4
18 64 2 2 128 2 >2 1 8 >16 16 4
Patient 6 19 32 4 2 32 2 >2 0.5 >512 >16 8 4
20 32 4 2 64 2 >2 0.5 >512 >16 16 4
21 16 4 2 64 2 >2 0.5 >512 >16 16 8
Patient 7 22 64 2 2 128 4 >2 1 16 >16 16 8
23 32 4 2 64 4 >2 1 16 >16 16 4
Patient 8 24 1 2 1 32 4 >2 0.5 16 >16 16 8
25 1 2 1 16 2 >2 0.5 16 >16 16 8
Patient 9 26 2 8 4 64 2 >2 1 16 >16 64 4
27 2 8 4 128 2 >2 1 16 >16 64 4
28 2 8 4 128 4 >2 1 16 >16 64 16
Control 29213 2 4 2 32 2 >2 0.5 16 >16 4 16  
1Cipro.=Ciprofloxacin 2Clind.=Clindamycin  3Pip/Tazo=Piperacillin/Tazobactam        4Vanco.=Vancomycin 
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also treated with piperacillin/tazobactam and a 2-fold increase was observed in the 
second isolate to this drug (2 µg/ml vs. 1 µg/ml).  Patient six was treated with 
piperacillin/tazobactam and showed a 2-fold increase in the second and third organisms 
isolated when compared to the first isolate collected (16 µg/ml vs. 8 µg/ml).  
Vancomycin was also used in patient six and a 2-fold increase was observed in the third 
organism isolated (8 µg/ml vs. 4 µg/ml).  The second isolate from patient seven showed 
a 2-fold increase in MPC with cefotaxime compared to the first isolate (4 µg/ml vs. 2 
µg/ml).  Patient nine was treated with both cephalexin and ciprofloxacin and increases 
in MPC were observed with both of these agents (cephalexin: >64 µg/ml vs. 64 µg/ml 
and ciprofloxacin: 4 µg/ml vs. 2 µg/ml).  Interesting MPC data were observed from 
patient four, since the first and last organism isolated from this patient (#12 and #16, 
respectively) showed a reduced susceptibility by MPC with many of the antimicrobials 
compared to the other organisms isolated from this patient (#13-#15).  The PFGE 
pattern of these isolates clearly showed that isolate #12 and #16 were a different species 
than #13-15.  The different speciation most likely accounts for the different MPC 
values.   
It is possible that the small increases in MPC values observed in the patients 
may only be due to chance or method reproducibility of the MPC test.  The 
reproducibility of the MPC test is consistent with the reproducibility of the MIC test, 
that is, one doubling dilution above and below the observed value (NCCLS, 2001c,d).  
However, further characterization of the isolates that resulted in elevated MPC 
organisms was necessary to verify if, indeed, the observed elevations were due to the 
reproducibility of MPC test. 
 3.8.1 Isolate Characterization 
The mecA gene codes for a PBP which has a low affinity for β-lactam agents.  
This mechanism of resistance is the most common for organisms that are resistant to β-
lactam antimicrobial agents.  Cefotaxime, cephalexin, and piperacillin/tazobactam are 
β-lactam antibiotics.  Patients one, six, seven, and nine had organism isolates that were 
collected later during infection which showed 2-fold increases in MPC compared with 
the organisms collected early on in infection.  These patients were treated with the β-
lactam agents mentioned above.  The isolates that had a 2-fold increase in MPC were 
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tested for the presence of the mecA gene.  The mecA positive control was provided by 
Dr. Harry Deneer, Head of Molecular Diagnostic Pathology at RUH and the University 
of Saskatchewan.  Each sample tested was negative for the mecA gene (Figures 3.30 and 
3.31).  Results from the isolate characterization were discouraging and, therefore, the 2-
fold increases observed in vancomycin and ciprofloxacin remain unexplained.  The lack 
of a large MPC increase as well as the lack of mecA in the organisms with elevated 
MPC values to β-lactams, led to the notion that the increases observed in vancomycin 
and ciprofloxacin were most likely due to the reproducibility of the MPC test (Blondeau 
et al, 2001), however, further investigations are still necessary. 
 This study was based on a small sample size (9 patients).  To completely assess 
the hypothesis that resistant subpopulations may be selected from large, heterogeneous 
populations, in vivo, a larger sample size is needed.  Various other confounding factors 
may play a role in the behavior of an infecting organism during the course of infection 
and increasing the sample size and stratifying the variables may help to make the 












   1    2    3    4    5    6    7   8 
Lane 1=123 bp Marker 
Lane 2=mecA-Positive Control 
Lane 3=29213 Negative Control 
Lane 4=MPC-elevated #1 
Lane 5=MPC-elevated #2 
Lane 6=MPC-elevated #3 
Lane 7=MPC-elevated #22 
Lane 8=MPC-elevated #23 
 
Figure 3.30: Polymerase chain reaction (PCR) for mecA in sequential S. aureus isolates 





















Lane 1=123 bp Marker 
Lane 2=mecA-Positive Control 
Lane 3=29213 Negative Control 
Lane 4=MPC-elevated #27 (from 
Cephalexin MPC plate) 
Lane 5=MPC-elevated #28 (from 
Cephalexin MPC plate) 
Lane 6=MPC-elevated #2 (from  
Piperacillin/Tazobactam 
MPC plate) 
Lane 7=MPC-elevated #20 (from 
Piperacillin/Tazobactam 
MPC plate) 






   1    2    3    4    5    6    7     8igure 3.31: Polymerase chain reaction (PCR) for mecA in sequential S. aureus isolates 
ith elevated MPC values to cephalexin and piperacillin/tazobactam (MPC-elevated). 
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4.0 DISCUSSION 
 S. aureus is a ubiquitous organism causing worldwide morbidity and mortality 
(Murray et al, 1998c).  Its ability to rapidly develop resistance has compromised the use 
of many antimicrobial agents.  Literature suggests that the inappropriate use of an agent 
leads to increased resistance (Drlica and Schmitz, 2002).  With increasing resistance 
worldwide, it is important for healthcare professionals to maintain the efficacy of 
antimicrobial agents through proper usage of agents (Drlica and Schmitz, 2002). 
 Dosing strategies are currently based on several variables, including MIC 
susceptibility testing, and achievable and sustainable drug concentrations.  Advantages 
of standardized MIC testing have resulted in its worldwide acceptability (Gould and 
MacKenzie, 2002).  Many isolates may be tested at one time making this procedure 
efficient.  Also, with MIC testing, results are available within 24 hr.  Rapid data 
collection is important for patients with serious bacterial infections.  Another advantage 
of MIC testing is that it is standardized and requires few laboratory materials, thereby 
reducing laboratory costs.  Also, microbroth dilution, E-tests, and Kirby-Bauer Disc 
Tests are MIC procedures that are relatively simplistic.  With its efficiency, 
reproducibility, rapidness, simplicity, and minimal cost, MIC testing quickly became 
the acceptable procedure for susceptibility testing. 
 MIC testing, nonetheless, has some disadvantages.  The procedure tests 
organisms at an inoculum of ~105 cfu/ml.  Often, in an infected patient, inocula as high 
as 1010 cfu/ml exist (Gould and MacKenzie, 2002).  With the spontaneous mutation 
frequency at one mutation for every 106-108 cells, inocula exceeding 106 cells have the 
potential to possess bacterial cells that have developed resistance via point mutations 
(Zhao and Drlica, 2001).  Testing with an inoculum of 105 cfu/ml may not be 
representative of the true susceptibility of the population when >105 cfu/ml exist at the 
site of infection (Blondeau, 2003).  It is known that large populations often contain 
resistant subpopulations (Allen, 2003).  The MIC may not predict the development of 
resistance, since the MIC utilizes a small inoculum in which resistant subpopulations 
 88
are most likely absent.  The MIC, therefore, may not accurately represent a drug 
concentration that will destroy all the cells in the population of infecting bacteria.  
Because resistance is increasing, it is important to assess the way in which agents are 
administered and ensure that the procedure is optimal.  New methods to help develop or 
modify dosing strategies are needed in order to minimize increasing resistance. 
 The MPC approach is novel in that it utilizes bacterial populations exceeding 
109 cfu/ml (Zhao and Drlica, 2002; Lu et al, 2003; Zhao et al, 2003).  One advantage 
the MPC approach has over the MIC method is that the MPC defines the drug 
concentration necessary to eradicate all cells, including any spontaneously arising 
resistant mutants (frequency of 10-6-10-8) which will be detected by using such high 
inocula.  The MPC test also provides a measurement of the drug concentration 
necessary to eradicate large bacterial populations.  The MPC is a concentration that 
could potentially prevent growth of all susceptible and first-step resistant phenotypes in 
a bacterial population.  Dosing strategies based on MPC testing may essentially slow 
down emerging resistance. 
 There are some disadvantages to MPC testing.  The procedure is lengthy and 
inefficient and is, therefore, not easily performed by most laboratories currently 
performing susceptibility testing.  Few isolates can be tested in one experiment.  The 
entire MPC test requires approximately four days as opposed to the MIC test which 
requires only 24 hr.  The procedure also requires the use of many materials which 
increases laboratory costs.  As such, a less demanding protocol for the MPC will be 
necessary before implementing the MPC test in laboratories.  This is currently under 
investigation. 
 Few MPC studies have been performed on agents other than the quinolones and 
few studies have determined MPC values against S. aureus (Metzler et al, in press; 
Zhao and Drlica, 2001).  It was, therefore, important to assess the applicability of the 
MPC to the organism, S. aureus, against both quinolone and non-quinolone agents.  
With the help of the MSW concept, MPC values may aid one in determining more 
potent agents as well as the agents least likely to select for resistance (Zhao and Drlica, 
2002).  Also, the MPC approach may help develop new dosing strategies that are aimed 
towards resistance prevention. 
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 Interest was initially in determining MPC values of methicillin-susceptible and 
methicillin-resistant strains of S. aureus against four fluoroquinolones.  The newer 
fluoroquinolones (gatifloxacin, gemifloxacin, moxifloxacin) have been reported to have 
enhanced activity against Gram-positive pathogens than do other agents (ciprofloxacin, 
levofloxacin) (Blondeau, 1999; Blondeau et al, 2003a).  Numerous investigations 
(summarized in Blondeau, 2001, 2002) have confirmed these observations reporting 
MIC90 values of 0.063-0.5 µg/ml for the newer agents and 0.25-2 µg/ml for the older 
compounds against methicillin-susceptible strains.  Determining the susceptibility 
patterns of MSSA and MRSA strains against non-quinolone agents became of interest 
during investigations with the quinolone agents. 
According to the MIC and MPC data presented, the most potent agent against 
MSSA isolates was gemifloxacin (MIC90=0.016 µg/ml and MPC90=0.125 µg/ml) and 
the most potent agent against MRSA isolates was vancomycin (MIC90=1 µg/ml and 
MPC90=8 µg/ml).  Garenoxacin also showed increased potency compared to the other 
agents tested in this study with an MPC90 value that was equal to 8 µg/ml for MRSA 
isolates.  With respect to the potency of the agents, the MPC values gave results similar 
to those derived from the MIC data.  The MPC values, however, were consistently 
higher than the MIC values.  This was one trend observed between the MIC and the 
MPC data.  This indicates that with increased inoculum, concentrations required to 
completely eradicate higher density cultures are higher than those concentrations 
obtained from standard susceptibility testing (MIC).  The increase in resistance may be 
due to the selection of subpopulations with higher levels of resistance compared to the 
majority of the population.  This may be a result of the inoculum exceeding the 
spontaneous mutation frequency (one mutation per 106-108 cells) which may lead to an 
increase in an organism’s level of resistance via point mutations (Zhao and Drlica, 
2001).  Naturally, the MPC values were higher than the MIC values, since a higher 
concentration would be needed to eliminate a more resistant population.  This increase 
was observed for all agents including the non-quinolones.  This increase was also 
observed in the isolates that were initially determined resistant by MIC testing (the 
majority being MRSA isolates).  One may expect the already resistant populations to 
result in the same MPC value as the MIC value.  This is because the MPC is defined as 
 90
the drug concentration required to eliminate first-step resistant cells present in a 
population (same as the MIC value of the resistant population).  However, this did not 
occur.  The original population was initially resistant (perhaps by an earlier mutation) 
and when the population was grown up to approximately 109 cfu/ml, there was a 
possibility that a spontaneous mutation may have occurred which further increased the 
level of resistance of the organism.  Therefore, the concentration required to prevent 
growth of the population was higher than the MIC.  This indicates that perhaps 
resistance occurred in a step-wise fashion, increasing the level of resistance upon 
selective pressure and an inoculum of approximately 109 cfu/ml.  The MPC, however, is 
more appropriate for bacterial populations that are deemed susceptible by traditional 
susceptibility testing, since it is, essentially, a method aimed at the prevention of first-
step resistant mutants (Blondeau, 2003).  The observation that MPC values were 
consistently higher than MIC values, including situations where the MIC value was 
already resistant according to the NCCLS, suggests that large bacterial populations 
increase their general level of resistance when exposed to elevated levels of drug.  
Consequently, resistance is not an all or none phenomenon, but appears to be more 
reflective of a step-wise process in which an organism can gradually decrease its 
susceptibility to an agent. 
Another general trend observed was that the MPC values for MRSA were higher 
than the MPC values for MSSA excluding azithromycin and vancomycin.  This may be 
explained by multi-resistance, indicating that resistance to one agent (methicillin in the 
case of MRSA) may also play a role in the reduced susceptibility to other families of 
agents, for example, the penicillins, fluoroquinolones, and cephalosporins (Samaha-
Kfoury and Araj, 2003).  This phenomenon has been observed in many bacteria 
including Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, 
Pseudomonas aeruginosa, and S. pneumoniae isolates (Blondeau, 2003; Samaha-
Kfoury and Araj, 2003).  The lack of elevated MRSA MPC values compared to MSSA 
MPC values in azithromycin and vancomycin implies that an organism’s susceptibility 
to methicillin has no effect on the susceptibility of that organism to agents such as 
azithromycin and vancomycin.  However, previous literature indicates that MRSA 
isolates are more likely to develop reduced susceptibility to vancomycin compared to 
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MSSA isolates (Hiramatsu, 1998; Hiramatsu et al, 2002; Srinivasan et al, 2002).  On 
the contrary, the data observed in this study do not indicate that MRSA isolates are 
more likely to develop a reduced susceptibility to vancomycin compared to MSSA 
isolates.  The elevated MRSA values to cefazolin indicate cross-resistance of S. aureus 
organisms among methicillin and cephalosporin agents.  The elevated MRSA values to 
quinolones indicate multi-resistance of S. aureus organisms among methicillin and 
quinolone agents.  According to the data presented, there was no correlation between 
resistance of S. aureus to β-lactams, such as methicillin (MRSA), and resistance to 
macrolides or glycopeptides.  There may, however, be a correlation between S. aureus 
resistance to β-lactams and other families of antimicrobial agents, for example, the 
fluoroquinolones. 
It has been argued that time spent above the MPC may be important for 
restricting the development of resistance (Blondeau et al, 2002b, in press; Hansen et al, 
2003).  This may appear contradictory to the well-known characteristic of 
fluoroquinolones, that is, their concentration-dependent antibacterial effects.  Blondeau 
et al (in press) argue that maintaining drug concentrations above the MPC for as long as 
possible does not contradict concentration-dependent killing, but complements it.  To 
my knowledge, kill studies with S. aureus (based on the MPC concept) have not yet 
been performed, however, such studies have been published with S. pneumoniae data 
(Blondeau et al, 2002b).  Studies with S. pneumoniae suggest that maintaining drug 
concentration above the MPC for extended durations was necessary to cause a high 
reduction (kill) in viable cells.  Specifically, Blondeau et al (2002b) suggested that drug 
concentrations need to be in excess of the MPC values for >4 hr to result in a >90% 
reduction in viable cells.  Blondeau et al (in press) indicated that not only was 
concentration an important predictor of outcome, but also time spent above the MPC.  
The authors state that “…drugs whose concentrations remain in excess of the MSW for 
longer periods of time over the dosing interval would be less likely to select for 
resistance” (Blondeau et al, in press).  Similar kill studies involving S. aureus and based 
on the MPC principles may show similar observations to those for S. pneumoniae.  
However, two limitations of these kill studies should be considered.  First, drug 
elimination does not occur in vitro as it does in vivo.  Second, the in vitro kill studies 
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lack immune responses generally observed in vivo.  Regardless, these in vitro 
experiments do suggest some interesting observations that require in vivo confirmation.  
Of the fluoroquinolones, moxifloxacin showed the greatest amount of time spent above 
the MPC level (T>24 hr) for 122 MSSA isolates, as did garenoxacin (T>24 hr) for 26 
MSSA isolates, at dosages recommended by the manufacturer. 
Some MPC90 values for particular agents were ≥16-fold above their 
corresponding MIC90 values.  This was apparent for agents such as azithromycin (16-
fold for MSSA and MRSA), cefazolin (32-fold for MSSA and MRSA), cloxacillin 
(>16-fold for MRSA), and gemifloxacin (32-fold for MRSA).  MPC values that were 
considerably higher than the MIC values (such as those ≥16-fold) suggests that to 
achieve and maintain drug concentrations in the serum at or above the MPC level, 
dosing would involve treating the patient at high drug concentrations (Blondeau, 2003).  
At such high concentrations, other factors must be considered including toxicity, 
increased side effects, and perhaps patient compliance if the dosing regimen requires 
the patient to administer the agent ≥3 times a day.  These data, therefore, must be 
assessed carefully and certain measures should be taken to ensure safety before 
treatment at high doses.  
Pharmacokinetic curves of the agents as well as MIC90 and MPC90 values 
provide useful information with potential clinical applications.  Based on the theory that 
the MPC prevents the growth of first-step resistant mutants, one may use these values to 
help determine agents least likely to select for resistance or agents that may safely be 
administered at or above the MPC (Blondeau et al, 2001).  Based on the MPC concept, 
the antimicrobial agent least likely to select for resistance is one which is potent and has 
a narrow MSW (Zhao and Drlica, 2001).  The MSW includes the concentrations of 
agent that exist between the MIC and MPC value (Zhao and Drlica, 2001).  With the 
help of pharmacokinetic curves, one can determine the amount of time the serum 
concentration is within the MSW.  Time spent in the MSW is a concern, since it has 
been shown that concentrations within this window lead to the selection of resistant 
subpopulations (Firsov et al, 2003).  Based on the data presented in this study and on 
the MPC/MSW concept, agents least likely to select for resistant subpopulations for 
bacteremic MSSA infections were moxifloxacin > vancomycin > cloxacillin > 
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gemifloxacin > garenoxacin > gatifloxacin = levofloxacin > cefazolin.  Azithromycin is 
not normally used for bacteremic infections since serum concentrations do not achieve 
necessary levels for eradication (MIC values are often above the maximum serum 
concentration).  For bacteremic MRSA infections, the agent least likely to select for 
resistance was vancomycin.  The next agent least likely to select for resistance was 
garenoxacin since the MPC level is below the maximum serum concentration indicating 
treatment based on MPC levels may be clinically achievable without additional adverse 
effects.  Garenoxacin is still an investigational compound and is yet to be approved for 
clinical use.  The remaining agents had MPC90 values above the maximum serum 
concentration.  Out of these seven agents, the agent with the least amount of time within 
the MSW was cloxacillin (~50 min) followed by moxifloxacin and cefazolin (serum 
concentrations are within the MSW for ~3 hr and ~4 hr, respectively).  The remaining 
six agents all had MIC90 values above the maximum serum concentration.  These data 
suggest that use of various quinolones for MRSA infections is questionable.  Applying 
the MPC data with the pharmacokinetic curves and the concept of the MSW, the most 
appropriate agent to use for systemic MSSA and MRSA infections based on the data in 
this study were moxifloxacin and vancomycin, respectively.  Clinical trials/studies, 
however, are necessary to confirm the in vitro results described in this study.  At this 
point, it remains speculative that these in vitro results would have similar outcomes in 
vivo.   
The MPC/MSW data analyzed were for drug concentrations within serum 
(systemic or bacteremic infections).  Often, antimicrobial agents are absorbed from the 
blood into other anatomical sites, thereby increasing drug concentrations at these sites.  
For example, garenoxacin concentrations achievable in alveolar macrophages are much 
higher than the maximum serum concentration (158.6 µg/ml after 2.2 hr of a single oral 
dose of 600 mg versus 9 µg/ml in the serum) (Andrews et al, 2003).  After 11.5 hr, the 
garenoxacin concentrations in alveolar macrophages are still relatively high at 76 µg/ml 
(Andrews et al, 2003).  Data showing garenoxacin concentrations which exceed the 
MPC90 indicate that at that site of infection, alveolar macrophages in this case, the MPC 
may be safely achievable and effective for both MSSA and MRSA (Andrews et al, 
2003).  Also, Honeybourne et al (2001) observed gatifloxacin concentrations exceeding 
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the MPC90 for both MSSA and MRSA in alveolar macrophages.  Alveolar macrophages 
had an average drug concentration of 69 µg/ml 2 hr after a single 400 mg oral dose.  
After 4 and 12 hr, drug concentrations in the alveolar macrophages were still elevated at 
77 and 62 µg/ml, respectively.  Like garenoxacin, gatifloxacin achieves high drug 
concentrations in the alveolar macrophages compared to the serum.  This indicates that 
MPC90 values may be achievable and effective when the infection is at the site of 
alveolar macrophages.  Moxifloxacin has also shown high drug concentrations in sites 
other than the blood.  Following a single 400 mg oral dose, after 2.2 hr, concentrations 
in the epithelial lining fluid, the alveolar macrophages, and bronchial mucosa are 20.7, 
56.7, and 5.36 µg/ml, respectively (Soman et al, 1999).  For MSSA, these 
concentrations are above the MPC90 level (0.5 µg/ml) and MPC90 levels may, therefore, 
be achievable and effective at eliminating an infection within these sites based on the 
MPC model.  For MRSA, concentrations may be achieved above the MPC90 in 
epithelial lining fluid and in alveolar macrophages, however, not in bronchial mucosa, 
since the maximum concentration was only 5.36 µg/ml and the MRSA MPC90 was 16 
µg/ml for moxifloxacin.  For infections at anatomical sites other than the blood, 
maximum drug concentrations differ from serum drug concentrations for azithromycin 
as well (Rodvold et al, 2003).  After a 500 mg dose once daily for five days,  Rodvold 
et al (2003) recorded azithromycin concentrations in the pulmonary sites of healthy 
volunteers.  At 4, 12, and 24 hr, azithromycin concentrations were 650±259, 669±311, 
and 734±770 µg/ml, respectively, in alveolar macrophages.   
This information indicates that although MPC90 values may be unachievable in 
the serum, these values may be achievable at other sites (such as the epithelial lining 
fluid and alveolar macrophages) based on maximum drug values at the site(s) of 
interest.  Note the pharmacokinetic curves displayed in this study indicate antimicrobial 
concentrations within serum.  Nonetheless, plotting of the MIC90 and the MPC90 as well 
as the MSW on these curves provides insight as to the potential effectiveness of these 
agents for bacteremic infections. 
Overcrowding was assessed with levofloxacin, a fluoroquinolone, and S. aureus 
isolate, #4.  According to the overcrowding data displayed in Table 3.7, the appropriate 
volumes to use for MPC testing would be between 25 and 150 µl, since these volumes 
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provided consistent results.  Also, it was previously determined in the laboratory that 
for S. aureus isolates, 100 µl of a culture containing ≥109 cfu/ml was appropriate for 
MPC testing (Metzler et al, in press).  There was no significant difference in MPC 
values when plating various volumes of inoculum.  The MPC values obtained, 
therefore, were likely the true values and not a result of overcrowding.  Based on these 
data, overcrowding does not appear to be an issue with the MPC test using levofloxacin 
and perhaps other fluoroquinolones with S. aureus. 
When subpopulations recovered from MPC plates were re-tested by MIC 
procedures, the results indicated a change in susceptibility of a population of cells.  The 
MPC-recovered subpopulations displayed elevated MIC levels compared to the MIC 
values of the original parental population.  The increase in MIC values suggests that 
while performing the MPC experiment, the selection of resistant subpopulations occurs.  
Vancomycin was the only agent that did not show this phenomenon, however, it is 
possible that the MPC-recovered population reverted back to a susceptible wild type 
population while in drug-free media (Hiramatsu et al, 2002).  Indeed, it has been 
observed that VRSA tend to lose their resistant phenotype while growing in the absence 
of vancomycin (Hiramatsu et al, 2002; Cui et al, 2003).  Before re-testing these isolates 
by MIC, they were grown on drug-free media.  It is possible that the lack of elevated 
MIC values upon retesting was due to the failure to provide a constant selective media 
and, therefore, the MPC-recovered populations were able to revert back to the wild 
type, susceptible cells as described by Hiramatsu et al (2002) and Cui et al (2003).  
Another explanation for the lack of elevated MIC values in isolates resulting in high 
MPC values to vancomycin was described by Blondeau (2003) and others (Tomasz et 
al, 1970; Novak et al, 1999) as vancomycin tolerance.  This was explained by Tomasz 
et al (1970) by the ability of bacteria to survive, but not grow in the presence of drug.  
Cui et al (2003) showed that after multiple passages of VRSA strains through drug-free 
media, the MIC of the strains decreased, however, the strains still had the potential to 
develop higher level of resistance to vancomycin (resistant subpopulations still thrived 
within the populations with lower MIC values).  Tolerant strains may, therefore, be 
undetected by standard susceptibility testing (Blondeau, 2003).  MPC testing, however, 
may be useful for the detection of these vancomycin tolerant organisms since the MPC 
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is designed to detect subpopulations with higher levels of resistance compared to the 
original population. 
The results from the vancomycin study were, indeed, disconcerting.  For MRSA 
isolates, the MPC90 value fell within the range of intermediate-resistant (NCCLS, 
2001a).  This was disturbing since it indicated the possibility of populations of S. aureus 
to have decreased susceptibility to vancomycin.  Indeed, it has been shown that high 
level vancomycin resistance may emerge from a S. aureus population initially 
expressing low level resistance to vancomycin (Haraga et al, 2002).  If strains of VRSA 
emerge from susceptible populations, this could have an incredible impact on patients 
infected with MRSA strains.  As discussed earlier, vancomycin is significant in treating 
life-threatening S. aureus infections, especially those with organisms resistant to β-
lactam agents (Hiramatsu, 2001).  Once an organism becomes resistant to vancomycin, 
there are limited alternatives. 
Because very few studies have been performed on the MPC values of S. aureus 
against vancomycin, further characterization of the recovered mutants was necessary to 
determine phenotypic or genotypic differences between the original susceptible 
population and the MPC-recovered population.  Recovered organisms at high 
vancomycin concentrations were evaluated by PCR and EM.  Each sample was negative 
for all vancomycin-resistant genes tested (vanA, vanB, vanC, vanC2/C3, vanD, vanE, 
and vanG).  The lack of common vancomycin-resistant genes in the MPC-recovered 
populations suggests that a different mechanism of resistance may be present in these 
isolates or that these populations were tolerant to vancomycin (Blondeau, 2003).   
Statistical analysis of the cell wall thickness between the susceptible parent 
population and the MPC-recovered population revealed that the recovered population 
had a significantly thicker cell wall than the susceptible population (Mann, 1998b).  
This suggests that while performing the MPC test, concentrations between the MIC and 
the MPC values will result in the selection of a subpopulation of cells which are at a 
higher level of resistance towards vancomycin compared to the majority of the original 
population, possibly due to the thickening of the cell wall.  The above data observed 
may indicate that S. aureus has the potential to become resistant to vancomycin due to 
dosing strategies that result in serum vancomycin concentrations within the MSW.  The 
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clinical impact of this observation is yet to be established and further in vitro 
investigations are necessary to further explain this phenomenon. 
Recovered isolates with high MPC values to azithromycin were tested for 
common macrolide-resistant genes (ermA, ermB, ermC, mefA/E, and msrA/msrB).  
Three of the recovered isolates tested were positive for the ermC gene.  The parents of 
these isolates were negative for the ermC gene.  A similar observation was made with S. 
pneumoniae isolates.  S. pneumoniae MPC-recovered populations showed the presence 
of mefA or ermB while the parents of these isolates lacked these genes.  The 
characterization of these isolates provided evidence that in the original susceptible 
population, a resistant determinant was absent or undetected, however, in the MPC-
recovered population (in which a resistant subpopulation may have been selected) the 
resistance determinant was detectable.  It is known that the mere presence of these 
macrolide-resistant genes confers resistance, not via a spontaneous mutation (Smith et 
al, 2003).  It is, therefore, puzzling as to when, where, and how the MPC-recovered 
populations acquired the resistance determinants.  These experiments appear to have 
provided valuable insight into the selection of macrolide-resistant determinants which 
may then be spread to other cells, thereby, conferring macrolide resistance, however, 
further investigation is needed. 
Few studies exist on the possibility of resistant subpopulations emerging from 
original susceptible populations, in vivo. Studies of multiple sequential organisms 
isolated from patients at different times during the course of therapy may provide 
evidence of the enrichment of resistant subpopulations from large heterogeneous 
bacterial populations, in vivo.  Sequential isolates from nine patients were analyzed for 
changes in MPC values.  Small changes observed, however, were considered as 
insignificant when resistance determinants were absent.  The MPC values of isolates 
have a reproducibility of one doubling dilution above and below the MPC value 
(Blondeau et al, 2001).  The increases observed were, indeed, only one doubling 
dilution above the preceding MPC value, therefore, it is likely that the increases were 
due to the reproducibility of the MPC test.  More studies need to be done to evaluate the 
possibility of resistant subpopulations emerging from large heterogeneous populations, 
in vivo. 
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The data presented provide a solid base for MPC data obtained with S. aureus 
organisms towards different antimicrobial agents.  The MPC appears to be applicable to 
not only the quinolone agents, but to non-quinolones as well.  For example, the data 
presented in this study suggest that applicability of the MPC to macrolides and to 
glycopeptides is a definite possibility.  However, since MPC relates to mutant 
prevention, it may not be representative of all forms of resistance especially those that 
are transmissible on mobile genetic elements.  For this reason, a Resistance-Prevention 
Concentration (RPC) may be more encompassing.  Whether the RPC can impact on 
existing resistance or serve to prevent resistance in a fashion similar to MPC requires 
more extensive investigations on a broader range of antimicrobial agents and genus and 
species of organisms than what has been completed to date.  Nonetheless, the data 
presented in this study provide evidence of resistance prevention at MPCs for both 
quinolone and non-quinolone agents as well as information regarding an agent’s 
propensity to select for resistance in large populations of S. aureus. 
It appears the MPC is an important parameter to consider in preventing 
resistance, in vitro.  The combination of the MIC, the MPC, and the MSW are important 
to help assess agents least likely to select for resistance, in vitro.  It is speculated that 
the MPC concept will be significant in the future when determining new dosing 
strategies aimed at preventing resistance in clinical cases, especially with respect to 
immunocompromised patients.  
4.1 Future Considerations 
Questions and future considerations have evolved from the data presented in this 
thesis.  Future experimentation should be done on macrolide-resistant genes found in 
MPC-recovered isolates to help determine when and how these bacterial populations 
acquired the genes.  Testing different inocula (105, 106, 107, 108, and 109) may help 
determine at which point the resistant genes are detectable.   
More studies need to be performed on VRSA isolates in hopes of discovering a 
genetic determinant or mutation(s) for the phenomenon of the thickening of the cell 
wall in these VRSA isolates.  A study comparing the DNA sequences of the genes 
involved in bacterial cell wall synthesis of VSSA and VRSA isolates may provide 
insight as to mechanism of resistance in VRSA isolates.   
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The MPC should further be assessed with non-quinolone agents to help 
determine its applicability to these agents.  The determination of genetic differences 
between susceptible parent populations and resistant subpopulations would strengthen 
the argument that the MPC (or RPC) is applicable to non-quinolone agents.   
Also, a more simplistic procedure should be developed for the MPC before its 
introduction into laboratories that test for antimicrobial susceptibilities.  This is 
currently under investigation.   
The MPC concept must be assessed in animal and human trials before clinical 
application.  This can be done by determining the amount of time necessary to achieve 
killing of bacteria with different concentrations of drug and different bacterial loads in 
animal models such as rats.  Recent preliminary experiments performed by Glen 
Hansen (personal communication) with rats indicate that resistant subpopulations can be 
selected out of large heterogeneous populations of cells with currently accepted dosing 
strategies (unpublished observation).  Currently under investigation are the effects of 
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6.0 APPENDIX A 
 
 6.1 Solutions and Buffers 
 
  10X TE Buffer 
Dissolve 12.1 g of Tris Base and 3.72 g of EDTA in 750 ml of distilled 
water.  Bring to pH 8.0 using HCl.  Adjust volume to 1 L and autoclave. 
 
10X TBE 
Dissolve 90.8 g of Tris Base, 15.4 g of Boric acid, and 0.37 g of 
disodium EDTA in 1000 ml of distilled water and autoclave. 
 
0.5 M EDTA 
Add 93.05 g of EDTA (disodium salt) to 400 ml distilled water.  Add 
NaOH pellets one at a time until the EDTA is completely dissolved.  
Bring the pH to 8.0 by adding 5 M NaOH.  Adjust volume to 500 ml and 
autoclave. 
 
0.1M Cacodylate Buffer 
Combine 16 g of sodium cacodylate (Mol. Wt. 160.0) with 920 ml of 




Dissolve 10 g of sodium sarcosinate in 70 ml distilled water.  Use of heat 
will aid in dissolving the sarcosyl.  Adjust volume to 100 ml and 
autoclave. 
 
1% Pulsed Field Agarose 
Add 1.0 g pulsed field agarose to 100 ml 0.5X TBE.  Boil until agarose 
is dissolved and cool to 50°C before pouring the gel.  Allow gel to 
solidify for a minimum of 30 min before use. 
 
1% Agarose Gel for PCR 
Add 0.35 g to 35 ml of TBE Buffer containing ethidium bromide (ETBr).  
Microwave on high until the agarose is completely dissolved.  Pour gel 
and allow it to solidify for ~30 min.  
 
2% Glutaraldehyde 
Add 10 ml of 25% Glutaraldehyde EM grade to 115 ml of 0.1M 
cacodylate buffer. 
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2% Osmium Tetroxide 
Add 1 g of osmium tetroxide to 25 ml distilled water. 
 
3% Uranyl Acetate 
Mix 1.5 g of uranyl acetate with 50 ml of 30% ethanol for at least 30 min 
and protect from light. 
 
Cell Suspension Buffer 
Combine 100 µl of 1M Tris-HCl (pH 7.2), 200 µl of 1M NaCl, and 1.0 
ml of 0.5M EDTA (pH 8.0).  Dilute to 10 ml with sterile distilled water. 
 
Epon-Araldite 
Mix 81 g of Epon 812, 66 g of Araldite 502, and 180 g DDSA.  Then add 
4.5 g of DMP30 and mix well. 
 
ETBr Buffer 
Add 50 µl of ETBr at 10 mg/ml to 1 L of TBE Buffer for a final ETBr 
concentration of 500 µg/ml. 
 
ETBr Solution For Staining a Pulsed Field Gel 
Combine 40 ul stock ethidium bromide with 400 ml of distilled of 
distilled water. 
 
Low Melting Point Agarose 
Dissolve 1 g into 100 ml of TE Buffer at pH 8.0.  Boil for 1-1.5 min and 
cool to 50-65°C in water bath. 
 
Lysis Buffer 
Combine 100 ul of 1M Tris-HCl (pH 7.2), 500 µl of 1M NaCl, and 1.0 
ml of 0.5M EDTA (pH 8.0).  Weigh out 20 mg of deoxycholate and 50 
mg of N-Lauroylsarcosine and add to above mixture.  Dilute to 10 ml 
with sterile distilled water. 
 
PFGE Running Buffer 
Dilute 300 ml of 10X TBE in 2700 ml of distilled water for a 
concentration of 1X TBE. 
 
Proteinase K Buffer 
Combine 50 ml of 0.5M EDTA (pH 8.0) and 10 ml of 10% N-
Lauroylsarcosine.  Adjust pH to 9.0, then dilute to 100 ml with sterile 
distilled water. 
 
Proteinase K/Proteinase K Buffer 
Add 25 µl of 20 mg/ml of Proteinase K to 10 ml of Proteinase K Buffer. 
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Reynold’s Lead Citrate 
Mix 1.33 g lead acetate, 1.76 g sodium citrate, and 30 ml of double 
distilled water that has been boiled to remove CO2.  Shake vigorously for 
1 minute then place on a magnetic stirrer for 30 min.  Add 8 ml of 1N 
NaOH (prepared fresh using 2.135 g of NaOH and 50 ml of double 
distilled deionized water).  Adjust to 50 ml using boiled deionized water.  
Mix well.   
 
Skim Milk 




Add 5 ml of 1M Tris-HCl pH 8.0 and 8 ml of 0.25M EDTA pH 8.0 into 
494 ml of distilled water. 
 
Toluidine Blue 
Mix 2.5 g of Toluidine Blue, 2.5 g of sodium borate, and 250 ml of 
distilled water for several hr. 
 
Tracking Dye 
Add 60 g of sucrose into 100 ml sterile distilled water to make a 60% 
sucrose mixture.  Add 0.25 g of xylene cyanol into 100 ml sterile 
distilled water.  Add 10mM Tris at pH 8.0.  Combine the 60% sucrose, 
the 0.25% xylene cyanol, and the Tris. 
 
TSA 
Add 40 g to 1 L distilled water.  Autoclave. 
 
Wash Buffer 
Combine 10 ml of 1M Tris-HCl (pH 7.6) and 20 ml of 0.5M EDTA (pH 
















7.0 APPENDIX B 
 
 7.1 PFGE Conditions 
 
  Initial Time: 5.3 seconds 
  Final Time: 34.9 seconds 
  Included Angle: 120 
  Voltage: 200V, 6V/cm 
  Run Time: 18 hr 

































8.0 APPENDIX C 
 
 8.1 Preparation of Antimicrobial Agents 
 
  Azithromycin 
Add 0.02 g of powdered agent to 2 ml of 95% alcohol.  At 94.5% purity, 
the final stock concentration is 9450 µg/ml. 
 
Cefazolin 
Add 2.5 ml sterile distilled water to 1000 mg of cefazolin.  The final 




Add 10 ml of sterile distilled water to a 500 mg vial of cefotaxime to 
yield a final stock concentration of 50 000 µg/ml. 
 
Cefuroxime 
Add 7.5 ml of sterile distilled water to a vial containing 750 mg of 
cefuroxime.  The final stock concentration is equal to 100 mg/ml. 
 
Cephalexin  
Five milliliters of 1M NH4OH is added to 0.05 g for a final stock 
concentration of 10 000 µg/ml. 
 
Ciprofloxacin 
Add 0.109 g to 9.896 ml of sterile distilled water for a final stock 
concentration of 10 000 µg/ml. 
 
Clarithromycin 
Dissolve 0.01 g in 1 ml of methanol. At 97.7% purity, the final stock 
concentration is 9770 µg/ml. 
 
Clindamycin 




Ten milliliters of sterile distilled water is added to 2.5 g of cloxacillin for 




Add 0.1 g of erythromycin into 1 ml of 95% alcohol for a final stock 
concentration of 10 000 µg/ml. 
 
Garenoxacin 
Dissolve 0.067 g of DES into 100 µl of DMSO.  Add 6.7 ml of sterile 
distilled water for a final stock concentration of 10 000 µg/ml. 
 
Gatifloxacin 
Dissolve 0.035 g into 10 ml of sterile distilled water.  At 93.3% purity, 
the final stock concentration is 3265.5 µg/ml. 
 
Gemifloxacin 
Eight milliliters of sterile distilled water is added to 0.1 g of powdered 








This agent is available in injection form at 25 mg/ml.  Dilute to desired 
concentration. 
   
  Moxifloxacin 
Add 0.015 g into 10 ml of sterile distilled water for a final stock 
concentration of 1 500 µg/ml. 
 
Rifampin 
Add 0.05 g into 5 ml of DMSO.  At 95% purity, the final stock 
concentration is 9 500 µg/ml. 
 
Piperacillin/Tazobactam 
Weigh out 0.03 g of tazocin (88.6% is piperacillin and 11.4% is 
tazobactam) and add to 2.64 ml of sterile distilled water.  Final stock 
concentration of piperacillin is 10 000 µg/ml.  Final stock concentration 
of tazobactam is 1295.5 µg/ml. 
 
Vancomycin 
Add 10 ml of sterile distilled water to a vial containing 500 mg of 






9.0 APPENDIX D 
 
 9.1 MIC Control Ranges for ATCC S. aureus Strain 29213 
 
  Azithromycin    0.5-2.0 µg/ml* 
  Cefazolin    0.25-1.0 µg/ml* 
  Cefotaxime    1.0-4.0 µg/ml* 
  Cefuroxime    0.5-2.0 µg/ml* 
Cephalexin    0.12-0.5 µg/ml† 
Ciprofloxacin    0.12-0.5 µg/ml* 
  Clindamycin    0.06-0.25 µg/ml* 
  Garenoxacin    Not Available 
  Gatifloxacin    0.03-0.12 µg/ml* 
  Gemifloxacin    0.008-0.03 µg/ml* 
  Gentamicin    0.12-1.0 µg/ml* 
  Levofloxacin    0.06-0.5 µg/ml* 
  Moxifloxacin    0.016-0.12 µg/ml* 
  Oxacillin    0.12-0.5 µg/ml* 
  Rifampin    0.004-0.016 µg/ml* 
Piperacillin/Tazobactam  0.25/4.0-2.0/4.0 µg/ml* 
  Vancomycin    0.5-2.0 µg/ml* 
 
  * NCCLS, 2001d 
  † http://www.fda.gov/cder/ogd/rld/50614s19.pdf 
 
 9.2 MIC Control Ranges for ATCC S. pneumoniae Strain 49619 
 
  Azithromycin  0.06-0.25 µg/ml* 
  Clarithromycin 0.03-0.12 µg/ml* 
  Erythromycin  0.03-0.12 µg/ml* 
 











10.0 APPENDIX E 
 
 10.1 Suppliers 
 
  10.1.1 Media 
 
 Mueller Hinton Broth (MHB)  Becton, Dickinson and Co., Sparks, MD 
 Todd Hewitt Broth (THB)  Becton, Dickinson and Co., Sparks, MD 
 Tryptic Soy Agar (TSA) with  Becton, Dickinson and Co., Sparks, MD 
  5% Sheep Blood 
 
  10.1.2 Antimicrobial Agents 
 
 Azithromycin    Pfizer Inc., Groton, CT 
 Cefazolin    Novopharm Limited, Toronto, ON 
Cefotaxime   Hoeschst-Roussel Canada Inc.,  
Montreal, QC 
 Cefuroxime    Eli Lilly Canada Inc., Toronto, ON 
 Cephalexin    Sigma Chemical, Steinheim, Germany 
Clarithromycin   Abbott Chemicals, Baceloneta, Puerto 
       Rico 
 Clindamycin    SABEX, Boucherville, QC 
 Cloxacillin    Novopharm Limited, Toronto, ON 
 Clindamycin E-test strips  AB Biodisk, Solna, Switzerland 
 Ciprofloxacin    Bayer, West Haven, CT 
Erythromycin    Novopharm Limited, Toronto, ON 
 Garenoxacin    Bristol Myers Squibb, Wallingford, CT 
 Gatifloxacin    Bristol Myers Squibb, Wallingford, CT 
 Gemifloxacin    GlaxoSmithKline Biologicals, Belgium 
 Gentamicin    Novopharm Limited, Toronto, ON 
 Levofloxacin    Janssen-Ortho Inc., North York, ON 
Moxifloxacin    Bayer, Mt. Prospect, IL 
Piperacillin/Tazobactam  Wyeth-Ayerst Canada Inc., Montreal, QC 
Vancomycin    Eli Lilly Canada Inc., Toronto, ON 
  
 10.1.3 Reagents, Chemicals, and Enzymes 
 
25% Glutaraldehyde (EM Grade) Marivac, St. Laurent, QU 
95% Alcohol    Commercial Alcohols Inc., Brampton, ON 
Agarose    Invitrogen, Corisbad, CA 
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Ammonium Hydroxide  BDH Inc., Toronto, ON 
Araldite 502    Ted Pella, Inc., Millville, NJ 
Boric Acid    BDH Inc., Toronto, ON 
Buffer A                                             New England BioLabs, Mississauga, ON 
Cefinase    BBL Microbiology Systems,  
Cockeysville, MD 
DDSA     Ted Pella, Inc, Millville, NJ 
(Dodecenylsuccinic Anhydride) 
Deoxycholate Acid   Sigma-Aldrich Co., St. Louis, MO 
DMP-30    Ted Pella, Inc., Millville, NJ 
[Tri(Dimethylaminoethyl Methacrylate)] 
EDTA     Sigma-Aldrich Co., St. Louis, MO 
Epon 812    Electron Microscopy Sciences, Fort 
Washington, PA 
Ethidium Bromide   BioRad Loaboratories, Hercules, CA 
Ethanol    Electron Microscopy Sciences, Fort  
      Washington, PA 
Hydrochloric Acid (HCl)  BDH Inc., Toronto, ON 
InstaGene Matrix   BioRad Laboratories, Hercules, CA 
Kodak D-19 Developer  Kodak 
Kodak Rapid Fixer   Kodak 
Lambda Ladder   New England BioLabs, Mississauga, ON 
Lead Acetate    Anachem, Bedfordshire, UK 
Lead Citrate    Ted Pella, Inc., Millville, NJ 
Low Melting Point   BioRad Laboratories, Hercules, CA 
 Agarose 
Lysostaphin    Sigma Chemical Co., St. Louis, MO 
Mass Ladder    Invitrogen, Burlington, ON 
N-Laurylsarcosine   Sigma Chemical Co., St. Louis, MO 
Osmium Tetroxide   Marivac, St. Laurent, QU 
PCR Ladder    Invitrogen, Carisbad, CA 
PCR Primers    Sigma-Genosys, Oakville, ON 
PuReTaq Ready-To-Go  Amersham/Pharmacia, Piscataway, NJ 
 PCR Beads 
Proteinase K    Sigma Chemical Co., St. Louis, MO 
Pulsed Field Certified Agarose Sigma Chemical Co., St. Louis, MO 
Saline     Baxter, Deerfield, IL 
Skim Milk    Becton, Dickinson and Co., Sparks, MD 
Slidex Pneumo-Kit   bioMerieux, Marcy-l’Etoile, France 
SmaI     New England BioLabs, Mississauga, ON 
Sodium Borate   Fisher Scientific, USA 
Sodium Cacodylate   Ted Pella, Inc., Millville, NJ 
Sodium Chloride (NaCl)  BDH Inc., Toronto, ON 
Sodium Citrate   BDH Inc., Toronto, ON 
Sodium Hydroxide (NaOH) Pellets BDH Inc., Toronto, ON 
Staphaurex    Remel Inc., UK 
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Sucrose    BDH Inc., Toronto, ON 
Tris-HCl    Sigma Chemical Co., St. Louis, MO 
Uranyl Acetate   Ted Pella, Inc., Millville, NJ 
Wizard Kit    Promega, Madison, WI 
Xylene Cyanol   BioRad Laboratories, Hercules, CA 
 
  10.1.4 Disposable Labware 
  
200 µl Pipette Tips   VWR International, Edmonton, AB 
Corning Cryovials   Corning Inc., Corning, NY 
Cuvettes    Fisher Scientific, USA 
Glass Tubes    Fisher Scientific, USA 
Latex Gloves    Fisher Scientific, USA 
McFarland Tubes   Fisher Scientific, USA 
Microcentrifuge Tube   Fisher Scientific, USA 
 Microtitre Plates   Sarstedt, Newton, NC 
Pasteur Pipettes   Fisher Scientific, USA 
 Sterile Plastic Petri Plates  Fisher Scientific, USA 
 Swabs     Fisher Scientific, USA 
Wooden Applicator Sticks  Puritan, Guilford, Maine 
  
  10.1.5 Equipment 
  
20 µl, 200 µl and 1 ml Pipettors Gilson Company, Inc., Lewis Center, OH 
 -70°C Freezer    Forma Scientific Inc., Marjetta, OH 
Avanti J-E Centrifuge   Beckman Coulter, Palo Alto, CA  
CHEF DRIII PFGE System  BioRad Laboratories, Mississauga, ON 
 Colorimeter    Hach Company, Loveland, CO 
 Hot Plate/Stirrer-Model 300T  Fisher Scientific, USA 
 PCR Gel Casting Mold  BioRad Laboratories, Mississauga, ON 
PFGE Gel Casting Mold  BioRad Laboratories, Mississauga, ON 
pH Meter    Corning Inc., Corning, NY 
 Pulsed Field Gel   BioRad Laboratories, Mississauga, ON 
Casting Apparatus 
Gel Doc 1000 Illuminator  BioRad Laboratories, Mississauga, ON 
Microcentrifuge   Brinkmann Instruments, Mississauga, ON 
 Microwave Oven   Samsung, Suwon, Korea 
Oxygen Incubator   Hotpack Corp., Philadelphia, PA 
 Shaking Water Bath   Mandel Scientific Co., Guelph, ON 
 Spectrophotometer   Pharmacia, Cambridge, England 
 Thermocycler (PCR Express) Thermo Hybaid, Ashford, Middlesex, UK  
 Vortex (Mini-Shaker Model 58) Fisher Scientific, USA 
 Weigh Scale – Mettler PC440 DeltaRange, Zurich, Switzerland  
 
